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ABSTRACT 
Lung cancer is the leading cause of cancer-related mortality worldwide. The main 
risk factor associated with lung cancer is cigarette smoking.  Research through the 
years suggests that nicotine in cigarettes promotes lung cancer by activating 
signaling pathways that lead to cell proliferation, cell survival, angiogenesis, and 
metastasis.  Nicotine’s cellular actions are mediated by its cognate receptors, 
nicotinic acetylcholine receptors (nAChRs).  Here, I describe the expression levels 
of all known human nAChR subunit genes in both normal and lung cancer cells.  
Of note, the genes encoding the α5, α3, and β4 subunits (CHRNA5/A3/B4) are 
over-expressed in small cell lung carcinoma (SCLC), the most aggressive form of 
lung cancer.  This over-expression is regulated by ASCL1, a transcription factor 
important in normal lung development and lung carcinogenesis.  The 
CHRNA5/A3/B4 locus has recently been the focus of a series of genetic studies 
showing that polymorphisms in this region confer risk for both nicotine 
dependence and lung cancer.  I show that CHRNA5/A3/B4 depletion results in 
decreased SCLC cell viability.  Furthermore, while nicotine promotes SCLC cell 
viability and tumor growth, blockade of α3β4 nAChRs inhibits SCLC cell viability. 
These results suggest that increased expression and function of nAChRs, 
specifically the α3β4α5 subtype, potentiate the effects of nicotine in SCLC.  This 
dual hit from the carcinogens in tobacco and the cancer-promoting effects of 
nicotine, may provide a possible mechanism for the increased aggressiveness of 
SCLC.  In addition, nAChRs can be activated by the endogenous ligand, 
 vi 
acetylcholine, which acts as an autocrine/paracrine growth factor in SCLC.  
Increased function of α3β4α5 nAChRs in SCLC could also potentiate 
acetylcholine’s mitogenic effects.  This mechanism, combined with other known 
autocrine/paracrine growth loops in SCLC, may help explain the ineffectiveness of 
available therapies against SCLC.  In an effort to add to the current arsenal 
against SCLC, I screened a 1280-compund library using a bioluminescence-based 
viability assay I developed for high-throughput applications. Primary screening, 
followed by secondary and tertiary verification, indicate that pharmacologically 
active compounds targeting neuroendocrine markers inhibit SCLC cell viability. 
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CHAPTER I. 
 
INTRODUCTION 
 2 
It’s easy to quit smoking.  I’ve done it hundreds of times. 
- Mark Twain 
 
I.A.Lung Cancer 
More than 1 billion people around the world smoke [1].  Approximately 10 
million cigarettes are sold every minute, resulting in more than 5 million deaths 
per year.  This makes tobacco use the leading cause of preventable deaths 
worldwide.  Roughly 600,000 of these deaths are due to second-hand smoke.  In 
the United States, overall tobacco use has been declining, though over 45 million 
adults still continue to smoke [2].   
 
Based on a recent Surgeon General’s report, the list of diseases linked to 
tobacco use is expanding [3].  Specifically, a causal relationship was described 
between active smoking and cardiovascular diseases, respiratory diseases, 
reproductive disorders, and several types of cancer, including cancers of the 
lung, bladder, cervix, esophagus, kidney, larynx, mouth, pancreas, stomach as 
well as leukemia. This is not surprising given that cigarette smoke contains 4,000 
chemicals, 250 of which are known to be harmful, and at least 50 of which are 
carcinogens.  The most potent of these carcinogens are polycyclic aromatic 
hydrocarbons and nicotine metabolites such as 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) and N-nitrosonornicotine (NNN).  These nitrosamines 
form DNA adducts that cause mutations leading to cancer [4]. 
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Smoking is estimated to cause more than 80% of lung cancer cases in 
developed countries [5].  In the United States, 24% of male smokers are 
expected to develop lung cancer in their lifetime, with a 5- to 10-fold increase in 
risk compared to non-smokers. The incidence rate for lung cancer in the country 
is surpassed only by that for prostate cancer in males and breast cancer in 
females [6].  
 
Lung cancer is one of the most common types of cancer, accounting for 
approximately 15% of all cancer cases worldwide [5].  It also remains the leading 
cause of cancer-related mortality around the world, resulting in more than 1 
million deaths per year.  In the United States, lung cancer poses a substantial 
economic burden on the healthcare system, averaging $6,250 monthly in total 
healthcare cost per patient [7].  Annual productivity loss due to the disease is 
approximately $23 billion for males and $14 billion for females [8].  Overall 
prognosis for the disease remains dismal, with 5-year survival rates ranging from 
6-14% for males and 7-18% for females [9]. 
 
Based on histological characteristics, lung cancer is classified into small 
cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC).  SCLC 
is the most aggressive type of lung cancer and has the poorest survival rate [10].  
SCLC arises from pulmonary neuroendocrine cells and can be grouped with 
other tumors that develop from these precursor cells, namely, typical carcinoid 
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tumors, atypical carcinoid tumors, and large cell neuroendocrine carcinomas [11]. 
Pulmonary neuroendocrine cells are either found in isolation throughout the lung 
and airways or in small groups called neuroepithelial bodies, typically found at 
bifurcations of small airways.  Neuroepithelial bodies synthesize 
neurotransmitters and neuropeptides as well as growth factors and vasoactive 
substances [12].  They play a trophic role in lung development and function as 
oxygen sensors and possibly chemo- and mechanoreceptors [13-15]. 
 
NSCLC can be subdivided into adenocarcinomas, squamous cell, and 
large cell lung carcinomas. Adenocarcinomas can be further classified as acinar, 
papillary, bronchioalveolar, solid adenocarcinoma with mucin production, and 
mixed subtypes [9].  Adenocarcinomas develop from small airway epithelial cells 
and alveolar type II cells while squamous cell carcinomas are derived from large 
airway epithelial cells.  Biomarker-guided therapies against NSCLC target 
specific cell types and subtypes [9, 16]. 
 
 
I.B. Nicotinic Acetylcholine Receptors (nAChRs) 
 
nAChRs are a heterogeneous family of ligand-gated cation channels 
activated by the endogenous neurotransmitter acetylcholine (ACh) and 
exogenous chemicals such as nicotine and its metabolites.  nAChRs were the 
first receptors to be characterized at the biochemical, biophysical, molecular, and 
pharmacological levels and have served as prototypes for all other ligand-gated 
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ion channels including those activated by 5-hydroxytryptamine (5-HT3), γ-
aminobutyric acid (GABAA and GABAC), and glycine [17, 18].  Binding of a ligand 
induces a conformational change that causes the channel to open, thereby 
allowing the flow of Na+, K+, and Ca2+ ions down their electrochemical gradients.  
The propensity of nAChRs to flux intracellular calcium levels is important in the 
activation of downstream signaling cascades [19]. 
 
nAChRs can be classified into two main categories: muscle or neuronal 
receptors.  Muscle nAChRs are expressed primarily in skeletal neuromuscular 
junctions and are composed of the α1, β1, δ, and ε or γ subunits [20].  In contrast, 
neuronal nAChRs were originally cloned from neuronal-like cell lines and brain 
cDNA libraries, hence their name, and are expressed throughout the nervous 
system where they increase neuronal excitability and facilitate synaptic 
transmission [20-22].  
 
The structure of nAChRs has been deduced using electron micrographs of 
nAChRs obtained from the electric organs of Torpedo rays, a marine ray that 
uses electrical discharge for defense and to stun prey [23].  nAChRs from these 
organs are highly homologous to vertebrate receptors.  High-resolution x-ray 
crystallography structures of the acetylcholine binding protein (AChBP) from 
mollusks have also been used to study the structure of nAChRs [23-26].  AChBP 
is a protein that resembles nAChRs but does not contain transmembrane and 
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cytoplasmic domains.  Like nAChRs, AChBP binds acetylcholine and is secreted 
into cholinergic synapses.  More refined details of the nAChR structure have also 
been provided by crystal structures of ligand-gated ion channels from 
prokaryotes [27-29].   
 
Neuronal nAChRs form pentameric structures assembled from a family of 
subunits that include α2-α10 and β2-β4 [24, 30-33].  Each nAChR subunit 
consists of an extracellular N-terminus, four transmembrane segments 
(designated M1-M4), a variable intracellular loop (100-200 residues) between M3 
and M4, and an extracellular C-terminus (Figure I-1) [34].  The N-terminus 
contains the ACh-binding domain, with the interface between adjacent subunits 
forming a hydrophobic pocket that contributes to the binding site [35].  The M2 
transmembrane segment of all five subunits forms the conducting pore of the 
channel, with regions in the M1-M2 intracellular loop contributing to cation 
permeability and agonist binding affinities [20, 34, 36].  The α subunits contain 
adjacent cysteines in their large extracellular domain that are important for ligand 
binding, whereas β subunits lack these residues [21].  Unlike other α subunits, 
however, α5 does not contribute to ligand binding.  Though it contains the 
viscinal cysteines, it is missing a key tyrosine residue (Tyr198) [37].  However, 
incorporation of the α5 subunit into a mature receptor alters receptor biophysical 
properties; it enhances receptor assembly and expression, reduces ligand-
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mediated upregulation, facilitates channel closure, and increases calcium 
conductance of the channel [38-40]. 
 
   
Figure I-1. Structure of nAChRs. A. Schematic representation of an individual 
nAChR subunit.  Each subunit consists of an extracellular amino (N) and 
carboxy (C) terminal, four transmembrane domains (M1-M4), and a large 
intracellular loop between M3 and M4. B. Five subunits co-assemble to form 
homomeric or heteromeric nAChR subtypes. White circles in the center of each 
pentamer represent the pore region.  Diamonds represent ligand binding sites. 
 
Much of what is known about the biophysical and pharmacological 
properties of nAChRs is based on studies in heterologous expression systems 
[20].  These systems make use of nAChR mRNA or cRNA injected into Xenopus 
oocytes as well as nAChR cDNA transfected into mammalian cell lines in order to 
express nAChR subunits singly or in combination.  The propensity of nAChR 
subunits to form either homomeric or heteromeric subtypes was determined by 
expressing subunits either singly or in combination.  When expressed alone, α7, 
A. 
B. 
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α8, α9, and α10 are able to form functional receptors that can be blocked by α-
bungarotoxin (α-BTx; Figure I-1B) [41-43]. In contrast, other α subunits require 
the presence of β subunits to form functional receptors [41, 44].  For instance, 
the α2 - α6 subunits can form heteromeric receptors with the β2 - β4.  In addition, 
α9 can form a heteromeric receptor with α10 [45, 46] and α7 can form a 
heteromeric receptor with β2 [47]. Each of these receptor subtypes has distinct 
electrophysiological and pharmacological properties [21, 31, 48, 49].  The 
functional diversity of the nAChR family offers abundant prospects for the design 
of novel therapeutics. 
 
I.C. nAChRs in the Nervous System 
Signaling through neuronal nAChRs underlies several fundamental 
processes in the nervous system both during development and in the adult [21].  
In the central nervous system (CNS), presynaptic nAChRs modulate release of 
many classical neurotransmitters including acetylcholine (ACh), glutamate, γ-
Aminobutyric acid (GABA), and norepinephrine [50].  Postsynaptic nAChRs are 
intimately involved in fast ACh-mediated synaptic transmission in addition to 
activity-dependent gene expression, which is critical for synaptic plasticity [21, 
22, 51, 52].  Within the peripheral nervous system (PNS), nAChRs mediate fast 
excitatory transmission in most, if not all, autonomic ganglia and are involved in 
modulating visceral and somatic sensory transmission [53-58].  
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The importance of nAChR-mediated signaling is reflected in the many 
pathologies in which cholinergic signal transduction is compromised.  Significant 
alterations in nAChR expression and function have been documented in several 
diseases such as Alzheimer’s disease, autosomal dominant nocturnal frontal 
lobe epilepsy, Parkinson’s disease, schizophrenia, Tourette’s disease, and 
megacystis-microcolon-intestinal hypoperistalsis syndrome [59-71].  In addition, 
nAChRs are key players in the development of nicotine addiction [72, 73].   
 
nAChRs in nicotine addiction 
Nicotine is one of the most widely consumed psychoactive drugs in the 
world and is the primary reinforcing chemical in tobacco [74].  Nicotine addiction 
is characterized by heavier smoking, early morning smoking, tolerance and 
withdrawal. Withdrawal involves both mood-oriented (affective) as well as 
physical (somatic) symptoms [75]. Withdrawal symptoms account for the high 
incidence of relapse in people attempting to quit smoking [76].  
 
At the molecular level, nicotine addiction is initiated by the binding of 
nicotine to nAChRs in the mesolimbic dopaminergic (DAergic) pathway, known 
as the reward circuitry of the brain [77-79].  Dopaminergic neurons in this circuitry 
originate in the ventral tegmanetal area (VTA) and project to the nucleus 
accumbens and the prefrontal cortex.  Activation of nAChRs in the VTA causes 
an increase in the firing of DAergic neurons, resulting in an increase of dopamine 
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(DA) release in the nucleus accumbens [80-83]. Elevation of dopamine levels in 
the nucleus accumbens is a phenomenon widely associated with the rewarding 
properties of drugs of abuse [79, 84].  Increase in dopamine levels is critical for 
the onset and maintenance of nicotine dependence and inhibition of dopamine 
elevation via lesions or pharmacological blockade attenuates the rewarding 
effects of nicotine [85] [86]. 
 
Several nAChR subtypes are robustly expressed in mesolimbic 
dopaminergic neurons, both at the level of the soma and at presynaptic 
terminals.  Expression of α4- and β2-containing receptors in the VTA is 
necessary and sufficient for nicotine-mediated DA elevation in the nucleus 
accumbens [87-90].  α4β2* nAChRs are critical for nicotine 
reward/reinforcement, sensitization, and tolerance [88, 90-92].  α5- and β4-
containing nAChRs as well as homomeric α7 nAChRs appear to be involved in 
the physical symptoms of withdrawal as evidenced by diminished somatic signs 
in α5, α7, and β4 KO mice [93-95].  Conversely, affective symptoms are readily 
observable in α5 and α7 KO mice.  Affective symptoms, however, are absent in 
β2 KO mice, suggesting that β2-containing nAChRs may play a role in this 
component of withdrawal [95, 96].  The various roles that nAChR subtypes play 
in the different stages of nicotine addiction emphasize the biochemical and 
functional differences among the nAChR subtypes. 
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I.D. nAChRs In Lung Cancer 
 
 
Though traditionally labeled “neuronal,” it has become evident that 
neuronal nAChRs are expressed in numerous cell types and tissues including 
endothelial cells, gastrointestinal tissue, glia, immune cells, keratinocytes, and 
lung tissue [97-107].  In the lung and airways, nAChR subunit transcripts have 
been detected using RT-PCR, qRT-PCR, and in situ hybridization and have been 
shown to be expressed at varying levels in normal and malignant cells [101, 108-
111].  Protein expression of a variety of these nAChR subunits has also been 
investigated using Western blot analysis while assembly of functional nAChRs on 
the cell surface has been determined using radioligand binding assays and patch 
clamping [101, 112-114].  The near ubiquitous expression of nAChRs in lung 
cells underscores the need to elucidate their functional relevance in normal 
physiology and in disease states.  
 
Through the years, it has become apparent that nAChRs in lung cells act 
as central mediators in the activation of cancer signaling pathways (Figure I-2) 
[115].  As early as 1989, Schuller and Hegedus showed that nicotine stimulates 
proliferation of a neuroendocrine lung cancer cell line, an effect that could be 
abolished by nAChR antagonists [116, 117].  Shortly thereafter, John Minna’s 
group showed that lung cancer cells do express nAChRs and that nicotine 
inhibits apoptosis in these cells [114].  Receptor-mediated effects of nicotine 
were subsequently recapitulated by other nAChR agonists such as cytisine and 
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the tobacco nitrosamines 4-(methlynitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 
and N-nitrosonornicotine (NNN). 
 
 
  
Figure I-2.  Key research findings implicating nAChRs in lung cancer etiology.  
Since the first report that nicotine promotes proliferation of lung cells to the 
recent series of genetic studies implicating nAChRs in lung cancer, mounting 
evidence suggest that nAChRs play a critical role in the pathogenesis of lung 
cancer.  
 
nAChR-mediated signaling begins with the binding of agonists to nAChRs, 
causing a conformational change that leads to the opening of the channel and 
the influx of cations such as Na+ and Ca2+ and the efflux of K+.  The resulting 
membrane depolarization opens the gates of voltage-operated calcium channels 
(VOCCs), leading to additional flow of Ca2+ [115].  Calcium influx triggers the 
secretion of mitogenic factors and activates signaling cascades involved in cell 
proliferation, apoptotic inhibition, metastasis, and angiogenesis – processes that 
are considered hallmarks of cancer (Figure I-3) [115, 118-120]. 
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nAChRs and cell proliferation 
Nicotine exposure alone does not appear to initiate lung cancer [121]. A 
more likely scenario is that nicotine promotes cancer after it has been initiated.  
In NSCLC and their normal cells of origin, nicotine triggers the release of EGF, 
leading to the binding of EGF to its cognate receptor EGFR, and activation of the 
Ras-Raf-MAPK cascade, a signal transduction pathway that leads to cell 
proliferation [122, 123].  Activation of the Ras-Raf-MAPK pathway can be 
abrogated by the α7 nAChR antagonists, α-BTx, and α-cobratoxin (α-Ctx) [124].   
 
Nicotine also induces fibronectin production, which activates the 
extracellular signal-regulated kinase (ERK), the phosphatidylinositol 3-kinase 
(PI3-K), and the mammalian target of rapamycin (mTOR), leading to cell growth 
and survival [125].  In addition, nicotine stimulates the expression of the 
peroxisome proliferator-activated receptor (PPAR-β/δ), an effect that can be 
blocked by α-BTx, α7 small interfering RNAs (siRNAs), and PI3-K and mTOR 
inhibitors [126].   
 
Carcinogenic nitrosamines such as NNK and NNN also promote cell 
proliferation by activating distinct signaling pathways.  NNK has a higher affinity 
for α7 nAChRs while NNN has a higher affinity for heteromeric nAChRs [127].  In 
SCLC, NNK evokes calcium influx and activates the Raf-MAPK pathway 
activation, resulting in the phosphorylation of c-myc [128, 129].  Tobacco 
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nitrosamines can therefore promote lung cancer through direct genotoxic effects 
or via nAChR-mediated mechanisms [130, 131].   
 
nAChRs and cell survival 
Nicotine confers resistance to the apoptotic effects of chemotherapeutic 
drugs, opioids, oxidative stress, and UV radiation [132-134].  The pro-survival 
effects of nicotine appear to involve the PI3-K-Akt pathway [135].  In non-
immortalized human airway epithelial cells, nicotine causes site-specific 
phosphorylation of Akt [136].  Akt is a known physiological kinase of Bcl-2 family 
members.  Consistent with this, nicotine exposure activates Bcl-2, a key anti-
apoptotic molecule while inactivating the pro-apoptotic proteins, Bad and Bax 
[132, 137, 138].  Similarly, NNK inhibits apoptosis by activating Bcl-2, an effect 
that can be blocked by inhibitors of PKC and ERK1/2 and by c-myc silencing 
[139].  Akt activation also leads to the upregulation of the X-linked inhibitor of 
apoptosis protein (XIAP) and survivin, both inhibitors of apoptosis [140], as well 
as β-adrenergic receptor and NF-κB activation [141, 142]. 
 
nAChRs and migration/invasion 
 
Nicotine exposure results in downregulation of the epithelial markers E-cadherin, 
β-catenin, and the tight-junction protein zonula occludens (ZO-1), with 
concomitant upregulation of the mesenchymal proteins, fibronectin and vimentin 
[143, 144]. This epithelial-mesenchymal transition (EMT) is a phenomenon 
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associated with increased cell mobility and invasion, key events in the process of 
metastasis.  Nicotine treatment, either though intraperitoneal injections or 
through dermal patches, promotes metastasis in immunocompetent mice [144].  
Additionally, NNK exposure leads to increased invasion and migration of lung 
cancer cells via ERK-dependent phosphorylation of calpains [145].  
Pharmacological inhibition of ERK or gene silencing of calpains abolishes this 
response. The pro-metastatic effects of nicotine and its metabolites may 
contribute to the aggressiveness of SCLC, a lung cancer type highly associated 
with cigarette smoking [10]. 
 
nAChRs and angiogenesis 
Angiogenesis, the process of forming new blood vessels, involves 1) 
activation of endothelial cells by angiogenic stimuli such as hypoxia and cytokine 
release, 2) degradation of the basement membrane by matrix 
metalloproteinases, and 3) proliferation and migration of endothelial cells towards 
the angiogenic stimuli, via a vascular endothelial growth factor (VEGF)-
dependent mechanism [146-149].  Vascular endothelial cells express nAChRs as 
well as other components of the ACh signaling machinery [97, 102].  In these 
cells, ACh also acts in an autocrine or paracrine fashion and modulates 
vascularization and remodeling [150, 151].  Nicotine and its metabolite cotinine 
can induce endothelial cell tube migration by stimulating VEGF expression in 
lung cancer cells, an effect that can be reduced by α-BTx, MLA, and 
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mecamylamine [151-154].  Inhibition of the MAPK and PI3-K pathways prevents 
nicotine-induced neovascularization [151]. Nicotine, in combination with estradiol, 
also enhances growth of lung cancer xenografts via increased VEGF secretion 
and angiogenesis [155].  Finally, nicotine stimulates accumulation of hypoxia-
inducible factor-1α (HIF-1α), a master regulator of angiogenesis [156].  
 
Autocrine/Paracrine Growth Loops 
Lung cancers secrete ACh and utilize the same ACh signaling 
components as normal lung cells [157, 158].  In these cells, ACh acts as an 
autocrine or paracrine growth factor that activates a feedback loop leading to cell 
proliferation. The non-selective nAChR antagonist mecamylamine inhibits lung 
cancer growth, suggesting that the ACh machinery can be exploited in the 
rationale design of therapeutics against lung cancer [159, 160].  Possible 
pathway points that can be targeted include ACh synthesis, ACh secretion, 
receptor activation, choline uptake, and downstream pathways [160-164]. 
Several other neurotransmitters and neuropeptides act as autocrine or paracrine 
growth factors in lung cancer including bombesin/gastrin-releasing peptide, 
bradykinin, catecholamines, cholecystokinin, galanin, litorin, neuromedin, 
neurotensin, ranatensin, serotonin, and vasopressin [165].  Bombesin and 
serotonin release has been shown to be dependent on protein kinase C (PKC) 
activation [119].   Interruption of these autocrine or paracrine growth signals may 
also serve as a viable therapeutic approach against SCLC. 
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Figure I-3.  Working model of nAChR-mediated cancer signaling.  nAChR 
agonists such as Ach, nicotine, and tobacco nitrosamines bind to and activate 
homomeric (red) or heteromeric (multicolored) nAChRs.  nAChR activation 
leads to the opening of the channel and the flow of Na+, K+, and Ca2+ ions down 
their electrochemical gradients.  Subsequent membrane depolarization opens 
voltage-operated calcium channels (VOCCs) and further increases intracellular 
calcium levels.  Calcium influx activates downstream signal transduction 
pathways leading to lung cancer cell survival, proliferation, migrations/invasion, 
and angiogenesis.  Calcium influx also triggers the release of neurotransmitters 
and neuropeptides that act as autocrine or paracrine growth factors.  Pathway 
components in red indicate those identified in SCLC and its precursor cells; 
those in green have been identified in NSCLC and its precursor cells; and those 
in purple have been identified in both types of lung cancer cells and their 
corresponding cells of origin.  
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I.E.  The CHRNA5/A3/B4 Lung Cancer Susceptibility Locus 
 
Recent advances in genetic technology have paved the way for large-
scale genome-wide association studies (GWAS), which involve screening 
hundreds of thousands of single nucleotide polymorphisms (SNPs) across 
thousands of subjects [166].  Such studies have implicated variants in the 
chromosome 15q24-25 region in the development of nicotine dependence and 
lung cancer.  This genomic locus, spanning 203 kb, contains the genes encoding 
the α5, α3, and β4 nAChR subunits (Figure I-4) [167, 168]. 
 
 
 
Figure I-4.  The human CHRNA5/A3/B4 gene cluster. The CHRNA5 gene is 
transcribed in the opposite direction as CHRNA3 and CHRNB4 (colored 
arrows). Blue boxes represent exons and red boxes represent untranslated 
regions.  Horizontal black lines indicate introns and horizontal gray lines 
indicate intragenic regions.  The boundaries for each gene are labeled with 
corresponding Genbank annotations. The non-synonymous D398N 
polymorphism (rs16969968) associated with nicotine dependence and lung 
cancer is indicated by an arrow under exon 5 of the CHRNA5 gene. 
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Expression patterns of the CHRNA5/A3/B4 genes 
Admixtures of the nAChR subunits encoded by the 15q24-25 locus form 
the predominant nicotinic receptor subtypes expressed in the PNS [169-173] as 
well as at key sites in the CNS [174, 175].  In the PNS, α3 subunit expression is 
seen in the dorsal root ganglia [176], facial motoneurons [177], retina [178, 179], 
adrenal, otic, and spenopalatine ganglia [171], the superior cervical ganglion 
(SCG), and trigeminal sensory neurons [172, 180].  In the CNS, the α3 subunit is 
expressed in the brainstem [181], cerebellum [182, 183], cortex [183, 184], 
hippocampus [99, 183-186], interpeduncular nucleus [174, 185, 187], medial 
habenula [174, 176], pineal gland [176], spinal cord [188, 189], substantia nigra 
[190], thalamus [186, 187], and the VTA [187, 191]. 
 
Outside of neurons, the α3 subunit is expressed in human oral 
keratinocytes [192-194] where its mRNA and protein expression levels are 
increased following exposure to nicotine [193-195].  α3-containing nAChRs are 
also expressed in bronchial epithelia [97, 101], the gastrointestinal tract [196, 
197], lymphocytes [198], oligodendrocyte type-2 astrocyte (O2A) progenitors 
[199], polymorphonuclear cells [198], and vascular endothelial cells [97, 102]. 
 
Similar to the α3 subunit, the α5 subunit is most highly expressed in the 
PNS, but is also expressed in several key regions of the CNS [191, 200].  In the 
PNS, α5 is expressed in most autonomic ganglia [180, 196] and the retina [178].  
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Centrally, α5 is expressed in the cerebellum and thalamus [196] but is also 
detected in the brainstem, cortex, habenula, hippocampus, interpeduncular 
nucleus, other midbrain nuclei, and the spinal cord [99, 174, 188-190, 201, 202].   
 
Outside the nervous system, α5 subunit expression has been detected in 
the gastrointestinal tract, thymus and testis [196, 197].  Furthermore, the α5 
subunit is expressed in many of the same cell types as the α3 and β4 subunits 
including bronchial epithelium [97, 101], O2A progenitors [199], oral epithelium 
[193, 194], vascular endothelial cells [97, 102], and a variety of immune cells 
[203]. 
 
The β4 subunit gene is widely expressed in the PNS, with relatively high 
expression in trigeminal sensory neurons [172, 180] as well as sympathetic 
neurons and the superior cervical, dorsal root, spenopalatine and otic ganglia 
[171, 176, 204].  The β4 subunit is also expressed in the adrenal medulla [205] 
with lower expression in the retina [178].  In the CNS, β4 expression is 
particularly high in the interpeduncular nucleus, medial habenula, olfactory bulb, 
and pineal gland [174, 185, 206] with lower expression in the cortex, cerebellum, 
hippocampus, midbrain, spinal cord, and thalamic nuclei, [99, 182, 187-190, 
207]. 
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Significant overlap of β4 expression with α3 and α5 expression is also 
observed outside the nervous system, β4 is expressed in multiple cell types of 
the bronchial epithelium [97, 101], intestines [196, 197], O2A progenitors, oral 
keratinocytes [193, 194], polymorphonuclear cells [198], and vascular endothelial 
cells [102],  [199].  Finally, as discussed in detail in Chapter II, β4 is co-
expressed with α3 and α5 in the lung and is upregulated in lung cancer [208-
210]. 
 
Transcriptional regulation of the CHRNA5/A3/B4 genes 
The co-expression of the CHRNA5/A3/B4 genes coupled with their 
genomic clustering hinted early on that they may share common regulatory 
mechanisms in addition to specific regulation of each gene.  Further support for 
this idea comes from several observations.  First, nucleotide sequencing of the 
individual gene promoters revealed that they each lack classical CAAT and TATA 
boxes [168].  Instead, the promoters are GC-rich and contain several binding 
sites for the transcription factors, Sp1 and Sp3 (Figure I-5).  Both Sp factors 
positively regulate transcription of each of the clustered subunit genes through 
multiple binding sites in each individual promoter [211-221].  Chromatin 
Immunoprecipitation (ChIP) experiments demonstrated Sp1 binding activity in the 
context of native chromatin for all three promoters [222, 223].  It is likely that Sp1 
is involved in tethering the basal transcription machinery to the TATA-less 
nAChR subunit gene promoters [224].  Second, in addition to the Sp factors, the 
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CHRNA3/A5/B4 promoter regions can directly interact with and be trans-
activated by the more spatially restricted regulatory factors Sox10 and SCIP/Tst-
1/Oct-6 [225-227].  Third, the mRNA levels of the CHRNA3/A5/B4 genes are 
coordinately up-regulated during neural development [228-230] and coordinately 
down-regulated following denervation [231].  Perhaps the most compelling 
evidence for a coordinated regulatory scheme comes from the Deneris lab, which 
showed that two transcriptional regulatory elements, termed β4 3’ enhancer and 
conserved noncoding region 4 (CNR4), play key roles in directing expression of 
the clustered nAChR genes in a tissue-specific manner. The β4 3’ enhancer is 
critical for expression in the adrenal gland and CNR4 is critical for expression in 
the pineal gland and SCG [232].  CNR4 is likely to play an important role in 
directing nAChR gene expression in the brain as well [232].  In addition to these 
shared regulatory features, the CHRNA3/A5/B4 genes are subject to gene-
specific regulation. 
 
In vitro experiments have shown that the paired-like homeodomain 
transcription factor, PHOX2A, regulates transcription at the α3 promoter [223].  
PHOX2A does not appear to bind directly to DNA, however, as the DNA-binding 
domain does not need to be completely intact for PHOX2A to regulate 
transcription [223].  Co-immunoprecipitation experiments demonstrate a physical 
interaction between Sp1 and PHOX2A, suggesting that PHOX2A is tethered to 
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the α3 promoter through its interaction with Sp1, similar to the interactions of Sp1 
with homeodomain transcription factors observed in other systems [233]. 
 
The POU domain factor SCIP/Tst-1/Oct-6 has been shown to positively 
regulate transcription from the α3 promoter in a cell-type-specific manner [227].  
Similar to PHOX2A, the POU domain factor SCIP/Tst-1/Oct-6 does not require 
DNA binding for transactivation of the α3 promoter [227].  Deletion analysis of the 
SCIP/Tst-1/Oct-6 transcription factor demonstrated that only the POU domain is 
needed for transactivation.  This transactivation does not depend on the 
presence of an Sp1 motif in the promoter region and is likely occurring through 
protein-protein interactions with other transcriptional machinery [225].  The 
transcription factor Brn-3a also trans-activates the α3 promoter, while the other 
members of the Brn-3 family, Brn-3b and 3c, modestly repress α3 promoter 
activity [234].  The positive regulation by Brn-3a is thought to be a result of 
protein-protein interaction as the α3 promoter lacks an obvious octamer or 
octamer-related binding site for Brn-3 factors [234]. 
 
The β4 3’ enhancer lies upstream of the α3 promoter in a region that 
overlaps with a 3’-untranslated exon of the β4 gene [235].  This enhancer 
element consists of two identical 37-base pair repeats separated by a 6-base pair 
spacer.  The β4 3’ enhancer acts in a cell-type-specific manner and enhances 
transcription from the α3 promoter in neuronal cultures [236].  The enhancer 
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contains several E-twenty six (ETS) factor-binding sites, mutation of which 
dramatically decreases, but does not completely abolish, α3 promoter activity.  
The ETS-domain binding factor, Pet-1, has been shown to activate reporter gene 
transcription in a manner that is both cell type - and β43’ enhancer - dependent 
[237].  Taken together, these studies suggest that Pet-1 interacts directly with the 
α3 promoter to activate transcription, though it likely requires additional cell-type-
specific co-factors.   
 
In vivo experiments using transgenic mice show that a larger DNA 
fragment between the α3 and β4 genes, containing both the β4 3´ enhancer and 
the α3 promoter, is capable of directing expression of a reporter gene to several 
areas of endogenous α3 expression in the brain [238, 239].  Surprisingly 
however, this DNA fragment did not direct reporter gene expression anywhere in 
the peripheral nervous system, in which the α3 gene is highly expressed, 
suggesting that elements in this fragment may be acting as repressors or that 
other sequences are necessary for peripheral expression. 
 
The presence of an intronic repressor element in the fifth intron of α3 has 
been reported [240].  The sequence of this α3 intron 5 repressor (α3I5) is highly 
conserved and is capable of bidirectional repressor activity in vitro.  Notably, cell-
type-specific repression of promoter activity was observed to be more potent in 
non-neuronal cell lines than in neuronal cell lines [240].  These data suggest that 
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this segment of DNA and the factors with which it interacts function to restrict 
expression of α3 to neuronal cell types.  The protein-DNA interactions that 
mediate this effect have yet to be elucidated.  The mechanisms regulating α3 
expression in non-neuronal cells remain largely obscure.  In Chapter II, we show 
that the transcription factor, achaete-scute complex homolog-1 (ASCL1), 
regulates the expression of α3 and β4 and modestly of α5 in lung cancer cells 
[208]. 
 
The α5 promoter region has been described in several genomic contexts 
including those in rodents and humans.  Transcription of α5 occurs in the 
opposite direction as α3 and β4, suggesting that in addition to transcription 
factors that regulate the entire cluster, distinct mechanisms may govern α5 
expression.  However, apart from the regulatory factors described above, little is 
known about these mechanisms. SCIP/Tst-1/Oct-6 does not appear to regulate 
α5 though it regulates α3 and β4.  No other transcription factors regulating α5 
expression have been reported, underscoring the need for more research efforts 
in this area. 
 
In addition to Sp1/2, Sox10 and SCIP/Tst-1/Oct-6, the β4 promoter is 
positively regulated by c-Jun [217].  Trans-activation by all of these factors is 
abolished when the Sp-binding site on the β4 promoter (referred to as the CA 
box) is mutated.  Conversely, synergistic activation of the β4 promoter is 
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observed when Sp1 is supplied in concert with Sox10, Sp3 or c-Jun [217, 218].  
Co-immunoprecipitation experiments demonstrated that all of these factors 
physically interact [241] and ChIP experiments confirmed that these interactions 
occur in the context of native chromatin [222].  These findings suggest the 
existence of a positively-acting multi-subunit transcriptional regulatory complex 
that assembles on the β4 promoter.  This is consistent with the hypothesis that 
Sp1 is critical for transcription at the β4 promoter and likely nucleates the 
regulatory complex that drives expression of the β4 gene. 
 
Two additional transcription factors have been shown to interact with the 
β4 promoter, Purα and heterogeneous nuclear ribonucleoprotein K (hnRNP K) 
[242, 243].  These proteins interact with another motif, the CT box, located 
directly upstream of the CA box.  hnRNP K is capable of repressing Sp factor-
mediated trans-activation of the β4 promoter [243] and also physically interacts 
with Sox10 [241].  Similar to hnRNP K, Purα physically interacts with Sox10 
[241].  Moreover, Pur! and hnRNP K themselves physically interact [241].  These 
proteins may participate in the multi-subunit complex described above to 
modulate expression of the β4 gene in the appropriate cellular context.  In vitro 
binding experiments demonstrated that each factor binds preferentially to the 
opposing single strand elements of the CT box, suggesting that some local DNA 
helix unwinding may occur [244].  Interestingly, Purα and hnRNP K have been 
shown to function together to negatively impact transcription of genes in other 
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systems and the same may be occurring at the β4 promoter [245].  In vivo 
experiments have also shown that a 2.3-kb fragment of the β4 promoter, 
containing the CA and CT boxes, is capable of directing reporter gene 
expression to brain regions that endogenously express β4, further supporting the 
importance of these elements in regulating β4 gene expression [246]. 
Figure I-5.  Transcriptional regulation of the CHRNA5/A3/B4 gene cluster.  A. 
Protein-DNA interactions at the CHRNA5/A3/B4 locus.  Colored circles indicate 
known transcription factors while circles with a question mark indicate 
transcription factors that have yet to be identified.  Regulation by the ASCL1 
transcription factor is described in Chapter II.  B.  Positive (red arrows) and 
negative (blue arrows) regulation of the CHRNA5/A3/B4 genes.  The β4 3’ 
enhancer, the β4 promoter region (SacI – HindIII fragment), and the distal 
CNR4 regions contain positive regulatory elements. The fifth intron of the 
CHRNA5 gene (A3I5) contains a repressor element. 
 28 
 Function of the CHRNA5/A3/B4 genes 
Knockout (KO) mouse models have been generated to determine the 
function of the clustered nAChR subunits.  Mice that do not express the α3 
subunit usually die within a week of birth due to multi-organ dysfunction [247].  
α3 KO mice develop enlarged bladders causing bladder infection, dribbling 
urination, and urinary stones – a phenotype resembling that of a rare human 
condition called megacystis-microcolon-intestinal hypoperistalsis syndrome [247].  
Consistently, patients with this disease do not appear to express α3 mRNA [60].  
α3 KO mice also display extreme pupil dilation and lack of pupil contraction in 
response to light.  Retinal wave activities have altered spatiotemporal properties 
delaying the refinement of retinal ganglion cell dendrites [247, 248].  Bladder 
contraction in response to nicotine is also lost.  Lastly, electrophysiological 
characterization shows that nicotine-induced whole-cell currents are abolished in 
the SCG of α3 KO mice. 
 
In contrast to the α3 KO mice, α5 and β4 KO mice are both viable and 
lack any gross abnormalities [247, 249, 250].  α5 KO mice do exhibit abnormal 
cardiac parasympathetic ganglionic transmission and are less sensitive to acute 
nicotine treatment.  Loss of α5 selectively affects axonal nAChRs in the SCG 
while leaving somatodendritic receptors unaffected [251].  Similarly, ganglionic 
transmission is impaired in β4 KO mice, attenuating ileal and bladder contractile 
responses to nicotinic agonists.  Nicotine-induced whole cell currents in the SCG 
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of β4 KO mice are also reduced but still present, suggesting that compensation 
from another subunit (i.e., β2) may be occurring [252].  Consistent with this 
notion, nicotine-induced currents in the SCG are abolished in double β2-β4 KO 
mice.  Moreover, double β2-β4 KO mice exhibit similar bladder and pupil 
dysfunction as α3 KO mice.  Taken together, these studies indicate that the 
clustered nAChR subunits are essential for normal ganglionic function and that 
compensation by β2 can occur with the loss of β4. 
 
In addition to their PNS-specific phenotypes, α3, α5 and β4 KO mice also 
exhibit CNS-centric abnormalities compared to WT mice.  For example, α3, α5 
and β4 KO animals are resistant to nicotine-induced seizures compared to their 
respective WT littermates and are not as sensitive to nicotine-induced inhibition 
of locomotion [253, 254].  β4 KO mice also appear less anxious compared to WT 
mice in two specific anxiety assays suggesting a role for β4* nAChRs in 
modulating anxiogenic stimuli [255].  These mice also have a lower core body 
temperature which is less responsive to modulation by acute nicotine infusion 
[256]. 
 
Risk alleles in nicotine addiction and lung cancer 
Genetic association between the CHRNA5/A3/B4 genes and nicotine 
dependence was first reported in an association study that compared nicotine-
dependent smokers versus those without symptoms of dependence [257].  
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Multiple SNPs were correlated with nicotine dependence, including rs16969968, 
located in the CHRNA5 coding region (Figure I-4).  This polymorphism changes 
an amino acid from aspartic acid to asparagine at position 398 (D398) in the 
major cytoplasmic loop of the α5 subunit.  This highly conserved aspartate 
residue is invariant across species such as frogs, chickens, rodents, cattle, and 
nonhuman primates [258].  Follow-up studies showed that one copy of the risk 
allele confers a 1.3-fold increase in risk for developing nicotine dependence, 
whereas subjects homozygous for the risk allele have almost a 2-fold increase in 
risk [259].  Since then, many groups have found rs16969968 and several other 
SNPs to be associated with different smoking behaviors using a variety of 
approaches and target populations [258-266]. 
 
Analogous large-scale genetic studies in lung cancer yielded results 
converging on the same variants in chromosome 15q24-25 [267-269].  This locus 
was found to account for 14% of lung cancer cases in a European population 
[267] and for 18% of cases in an Icelandic population [268].  rs16969968 was 
again found to be among the SNPs with the strongest disease association [269].  
Consistently, a candidate gene study showed that the rs16969968 risk allele is 
associated with increased risk for lung adenocarcinomas in an Italian population 
[270].  Another (synonymous) SNP highly associated with lung cancer is 
rs1051730, found in the coding region of CHRNA3 [267, 268]. 
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Because the chromosome 15 region is associated with both nicotine 
dependence and lung cancer, it raises the question of whether lung cancer is 
directly influenced by the genetic variants or merely the consequence of smoking 
behaviors.  Genetic evidence for the two lines of reasoning exist.  Increased lung 
cancer risk in non-smokers supports the view that the polymorphisms have a 
direct effect on lung cancer [271].  Additionally, the polymorphisms were not 
associated with other smoking-related cancers such as head and neck cancers 
including those of the oral cavity, larynx, pharynx, and esophagus [271].  
Association with lung cancer also persists even after accounting for cigarette 
consumption [167, 272, 273].  However, one study argues that cigarette 
consumption per se might not be a proper measure as individuals who smoke the 
same number of cigarettes per day exhibit varying levels of carcinogen and toxin 
exposure [274].  In fact, carriers of some risk variants ingest more tobacco toxins, 
possibly by inhaling more frequently and more deeply while smoking.  
Additionally, the CHRNA5/A3/B4 genes have also been linked to other smoking-
related disorders such as chronic obstructive pulmonary disease (COPD), 
peripheral arterial disease, and alcoholism [268, 275, 276].   
 
To distinguish between the two possibilities, direct evaluation of the 
biological function of specific SNPs needed to be performed.  A reasonable 
candidate for initial studies was the rs16969968 SNP, as it encodes a non-
synonymous SNP in CHRNA5.  Indeed, heterologous expression of the α5 cDNA 
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containing this SNP, along with α4 and β2, was carried out in HEK293T cells 
[258].  In this study, agonist-induced changes in intracellular calcium were 
measured using an aequorin-based luminescence assay.  α4β2α5 nAChRs with 
the asparagine variant exhibited lower maximal response to the nAChR agonist, 
epibatidine, indicating that the α5 risk allele is associated with reduced function 
of α4β2α5 nAChRs.  This work provides direct evidence that a variant associated 
with nicotine dependence and lung cancer alters biological function.   
 
Additional mechanistic evidence for the role of nAChR variants in nicotine 
dependence is provided by work showing that rs3841324, a SNP found in the 
non-coding region of α5, is associated with altered α5 mRNA levels in the brain 
[277].  rs3841324 is characterized by an insertion/deletion located upstream of 
the α5 coding region.  In this study, individuals homozygous for the minor allele 
(deletion) exhibit a 2.9-fold increase in CHRNA5 mRNA levels.  rs3841324 is in 
high linkage disequilibrium with other SNPs in this region.   Consistently, these 
SNPs are also associated with altered CHRNA5 mRNA expression. 
 
Combined analyses of the above biological mechanisms demonstrate that 
the risk allele of rs16969968 primarily occurs on a low CHRNA5 expression 
background [277].  Moreover, a combination of low mRNA expression and the 
presence of the non-risk allele confer protection for both nicotine dependence 
and lung cancer.  In normal lung tissue, rs16969968 also correlated with 
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CHRNA5 mRNA levels (i.e., an inverse relationship was observed between risk 
allele dosage and mRNA levels) [270].  The same study showed a 30-fold 
upregulation of CHRNA5 mRNA levels in lung adenocarcinoma compared to 
normal lung tissue.  In contrast, no differences in expression between cancer and 
normal samples were observed for the other genes in chromosome 15 outside 
the CHRNA5/A3/B4 gene cluster.  Taken together, the aforementioned studies 
offer two mechanistic bases for the association of nAChR variants with nicotine 
dependence and lung cancer: altered receptor function and aberrant gene 
expression.  
 
In this dissertation, the overarching goal is to elucidate the mechanisms 
underlying the role that α5α3β4 nAChRs play in lung cancer, with particular 
emphasis on SCLC, the most aggressive type of lung cancer.  Here we show that 
the CHRNA5/A3/B4 genes are over-expressed in SCLC and are regulated by 
ASCL1, a transcription factor of the Notch signaling pathway that directs the 
neuroendocrine phenotype of SCLC.  We then show that genetic depletion or 
pharmacological blockade of CHRNA5/A3/B4 depletion inhibits SCLC cell 
viability.  Consistently, silencing of CHRNA5 in vivo inhibits tumor growth.  
Finally, we show that the neuroendocrine phenotype of SCLC allows its targeting 
by pharmacologically active compounds. 
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Chapter II:   
EXPRESSION AND REGULATION OF THE CHRNA5/A3/B4 GENE CLUSTER 
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The most exciting phrase to hear in science, the one that heralds the most 
discoveries, is not "Eureka!" but "That's funny..." 
- Isaac Asimov 
 
II.A.Introduction 
Lung cancer is the leading cause of cancer-related mortality across the 
globe [5].  Cigarette smoking and second-hand smoke are the major etiologic 
factors associated with lung cancer, accounting for nearly 90% of all lung cancer 
deaths.  Given that 25% of adults smoke, a considerable number of people are 
presently at risk for the disease. 
 
Lung cancer is classified into two main histological types: small cell lung 
carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC).  The latter can 
be further divided into large cell carcinoma, adenocarcinoma and squamous cell 
carcinoma.  SCLC, a neuroendocrine tumor, is the most aggressive among the 
various types of lung cancer and has the poorest prognosis, with a 5-year 
survival rate of 15% [10].  This can reach as low as 2% for patients diagnosed 
with late-stage disease.  Though most patients respond to initial cycles of 
chemotherapy, they eventually become chemoresistant. 
 
Nearly all SCLC patients (>95%) have a history of cigarette smoking [10].  
This strong etiologic link is not surprising given the fact that tobacco contains at 
least 55 carcinogens, the most potent of which are nicotine-derived nitrosamines 
such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) [131].  Increasing 
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evidence also suggest that nicotine itself may directly contribute to 
carcinogenesis by inducing cell proliferation, transformation, apoptotic inhibition, 
and angiogenesis [115].  
 
Nicotine and NNK are both exogenous ligands of nicotinic acetylcholine 
receptors (nAChRs) [127].  nAChRs are transmembrane ligand-gated ion 
channels that have been extensively studied with respect to their role in 
fundamental physiological processes such as muscle contraction, attention, 
arousal, anxiety and learning and memory [278].  They are key players in the 
nicotine reward pathway, making them attractive drug targets for smoking 
cessation therapies [83, 84, 88, 279]. 
 
nAChRs have traditionally been referred to as either “muscle” or 
“neuronal” based on their expression patterns and subunit composition. Muscle 
nAChRs are made up of α1 subunits combined with β1, γ, δ, or ε subunits.  Here 
we focus on neuronal nAChRs, pentameric proteins made up of homomeric or 
heteromeric combinations of α and β subunits that include α2 – α10 and β2 – β4 
[278].  The precise combination of subunits determines the pharmacological and 
biophysical properties of the receptor [20, 32].  While the complete repertoire of 
native nAChRs has not been fully elucidated, it is clear that a staggering diversity 
of receptor subtypes and functions may exist [32].   
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The neuronal nAChRs have also been found in non-neuronal tissues [105, 
107, 203].  In particular, they are expressed in normal as well as lung cancer 
cells [209, 210].  The two most well-characterized nAChRs in this system are the 
homomeric α7 and the heteromeric α4β2 subtypes [280].  Recently, however, a 
series of genome-wide association studies pointed to a possible role for the 
nAChR α3β4α5 subytpe in the etiology of lung cancer [267-269, 281].  These 
studies identified a lung cancer susceptibility locus in the long arm of 
chromosome 15 (15q24/15q25.1), a genomic region containing the genes 
encoding the α5, α3, and β4 subunits (CHRNA5/A3/B4).  Single nucleotide 
polymorphisms found in the gene cluster were also found in independent studies 
to be associated with nicotine addiction [282-288].  It is not yet clear how variants 
in this locus may modulate the function of mature nAChRs but these studies do 
prompt further investigation on the role of these nAChR subunits in lung cancer. 
 
To address this gap in knowledge, we first examined the expression 
profile of these genes as well as all other neuronal nAChR genes in lung cancer 
cell lines and patient samples.  Here we describe the over-expression of the 
clustered nAChR genes in SCLC.  Furthermore, we identified a transcription 
factor, ASCL1, that regulates the CHRNA3/A5/B4 gene cluster in this tumor type.  
ASCL1 (termed Mash1 in rodents, hASH1 in humans) is a basic helix-loop-helix 
transcription factor that binds to DNA recognition motifs known as E-boxes [289].  
It is over-expressed in SCLC and other neuroendocrine tumors.  ASCL1 
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expression appears to be important for SCLC tumor initiation while its knockdown 
causes cell cycle arrest and apoptosis [290, 291].  In addition, transgenic mice 
that constitutively express ASCL1 and the SV40 Large T antigen develop 
aggressive lung tumors with neuroendocrine features [292].  Over-expression of 
ASCL1 in SCLC may thus lead to corresponding over-expression of the clustered 
nAChR genes, providing a mechanism by which nicotine’s effects may be 
potentiated in SCLC, contributing to its increased tumorigenicity. 
 
II.B.Materials and Methods 
Cell lines. Cell lines were obtained from the American Type Culture Collection 
(ATCC).  The SCLC cell lines used were DMS-53, DMS-114, NCI-H69, NCI-H82, 
NCI-128, NCI-146, NCI-H209 and NCI-446.  The NSCLC cell lines used were the 
large cell lung carcinoma cell lines NCI-H460, NCI-H661, NCI-1581 and NCI-
H1915; the lung adenocarcinoma cell lines A549, NCI-H838, NCI-H1395, NCI-
H1734 and NCI-H1793; and the squamous cell lung carcinoma cell lines NCI-
H520, NCI-H1869, NCI-H2170, SK-MES-1 and SW-900.  The normal lung cell 
lines used were BEAS-2B, HBE4-E6/E7, LL-24 and WI-38.  Cell lines were 
maintained in ATCC-recommended media at 37oC and 8% CO2. 
 
Patient samples.  Tissue samples were obtained from the UMass Cancer Center 
Tissue Bank and the Cooperative Human Tissue Network.  Approval from the 
University of Massachusetts Medical School Institutional Review Board was 
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obtained prior to sample collection. To date, a total of 123 cancer and normal 
lung tissues have been collected consisting of 53 normal, 7 SCLC and 63 
NSCLC tissues including 19 adenocarcinomas, 32 squamous cell lung 
carcinomas and 12 large cell lung carcinomas (Table II-1).  Samples were either 
snap-frozen surgically resected tissues or fresh pleural effusions.  Available 
normal attached tissues or age and sex-matched normal tissues were used as 
controls. 
Table II-1.  Clinical characteristics of lung cancer patient samples 
Specimen ID Histology Sex Age Stage Smoking 
History 
143C SCLC M 54 Extensive + 
985T SCLC M 71 T1N0M0 + 
1662T SCLC M 59 Extensive + 
1090251A2 SCLC M 57 NA* NA 
08-02-A280a SCLC M 61 T2N2MX NA 
06-11-A306aa SCLC F 72 NA NA 
MAD09-131T SCLC M 53 T2N0MX + 
350T Large Cell M 51 T2N0MX + 
808T Large Cell F 45 T2N1M0 + 
849T Large Cell M 74 T3N1M0 + 
1722T Large Cell F 74 T2N0MX NA 
MAD02-1005T Large Cell M 76 T2N0MX + 
MAD05-467T Large Cell F 61 T1N0MX + 
MAD07-597T Large Cell M 73 T1N0MX +  
MAD07-661T Large Cell M 71 T1N2MX + 
MAD07-809T Large Cell F  70 T2N0MX + 
MAD08-469T Large Cell M 61 T2N0MX + 
MAD08-638T Large Cell M 44 T2N1MX + 
Z4312A1E Large Cell M NA T2N2MX NA 
343T Adenocarcinoma M 62 T1N0MX + 
363T Adenocarcinoma F 56 T1N2MX + 
423T Adenocarcinoma M 64 NA + 
457T Adenocarcinoma M 64 T4N1MX + 
43089A1C Adenocarcinoma F 81 NA NA 
43464A1C Adenocarcinoma F 59 NA + 
43471A1C Adenocarcinoma F 26 T3N2MX - 
44833A1A Adenocarcinoma F 82 NA + 
45139A1D Adenocarcinoma F 61 NA + 
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45151A3CA Adenocarcinoma NA NA NA NA 
45514A1A Adenocarcinoma NA NA NA NA 
45607A1BA Adenocarcinoma M 78 NA + 
46127A1BA Adenocarcinoma M 77 NA + 
46244A1A Adenocarcinoma F 66 T4N1MX NA 
46598A1A Adenocarcinoma M 67 NA + 
1081210A1 Adenocarcinoma NA NA NA NA 
1090694A1 Adenocarcinoma F 66 NA NA 
08-04-A123A Adenocarcinoma M 67 NA NA 
Z4364A1A Adenocarcinoma F NA T2N1MX NA 
258T Squamous F 74 T1N0MX + 
318T Squamous M 81 T2N1MX + 
43312T Squamous F 76 NA NA 
43751T Squamous NA NA T2N1MX NA 
43057A1I Squamous M 68 NA + 
45843A1F Squamous M 41 NA NA 
46215A1F Squamous F 75 NA NA 
46830A1A Squamous NA NA NA NA 
1082331B2 Squamous F 69 NA NA 
1090147A2 Squamous M 72 NA NA 
3081395A3 Squamous F 51 NA NA 
3081583A5 Squamous F 70 NA NA 
3090415A2 Squamous M 56 T2N0MX NA 
08-01-A310A Squamous M  61 NA NA 
08-02-A290A Squamous F 58 T2N0MX NA 
08-05-A023B Squamous F 75 NA NA 
08-07-A078A Squamous F 65 T2N0MX NA 
08-08-A097B Squamous M 58 T2N1MX NA 
08-09-A190A Squamous M 58 NA NA 
08-11-A001B Squamous M 63 T1N1MX NA 
08-12-A011A Squamous M 74 T1N0MX NA 
09-03-A012B Squamous M 70 T1N2MX NA 
09-04-A019A Squamous M 75 NA NA 
MAD06-482T Squamous M 65 T1NXMX + 
MAD06-552T Squamous M 73 T1NXMX + 
MAD06-597T Squamous F 73 T1N0MX + 
MAD06-603T Squamous F 71 T1N0MX + 
MAD06-625T Squamous M 74 T2N1MX + 
Z3770A1A Squamous NA NA T3N0MX NA 
Z4129A1D Squamous M NA T2N1MX NA 
Z4363A1A Squamous M NA T2N1MX NA 
Z4640A1A Squamous F NA T2N0MX NA 
* NA – information not available 
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Quantitative RT-PCR. Total RNA was isolated from the cell lines and patient 
tissues using a RiboPure Kit (Ambion).  cDNAs were generated using a 
RETROscript Kit (Ambion).  Quantitative RT-PCR was performed using an 
Applied Biosystems 7500 Real-Time System and TaqMan assays for nAChR α2-
α7, α9-α10 and β2-β4 (Applied Biosystems, see Table II-2).  α8 gene expression 
was not analyzed because its expression has only been observed in avian 
species.  Samples containing no reverse transcriptase were used as negative 
controls. Relative gene expression was calculated using the 2-ΔΔCt method. The 
housekeeping gene β2-microglobulin was used as the endogenous control. 
 
Table II-2. TaqMan assays used to measure mRNA expression of nAChRs 
Target Gene TaqMan Assay 
CHRNA2 Hs00181237_m1 
CHRNA3 Hs00609519_m1 
CHRNA4 Hs00181247_m1 
CHRNA5 Hs00181248_m1 
CHRNA6 Hs00610231_m1 
CHRNA7 Hs01063373_m1 
CHRNA9 Hs00214034_m1 
CHRNA10 Hs00220710_m1 
CHRNB2 Hs00181267_m1 
CHRNB3 Hs00181269_m1 
CHRNB4 Hs00609523_m1 
β2-microglobulin Hs00187842_m1 
 
ASCL1 knockdown.  Knockdown of ASCL1 expression was performed in a SCLC 
cell line, DMS-53 and a NSCLC cell line, A549.  To control for off-target effects, 
three different siRNAs against ASCL1 were used namely s1656, s1657, and 
s1658 (Applied Biosystems).  Transient transfections were performed using 
Lipofectamine™2000 (Invitrogen).  Knockdown levels were determined using 
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quantitative RT-PCR.  A negative control siRNA (Applied Biosystems) that does 
not target any known human, mouse, or rat gene was used to normalize gene 
expression.  Untransfected samples were also analyzed for baseline gene 
expression.  Corresponding changes in nAChR α3, α5, and β4 gene expression 
was measured using quantitative RT-PCR with β2 microglobulin as endogenous 
control.  To determine specificity, gene expression of β2 was also measured.  
GAPDH levels were measured as a negative control.  Samples were analyzed in 
triplicate and at least two independent experiments were done for each siRNA. 
 
Western Blot Analysis.  Western blot analysis was performed using standard 
procedures to determine ASCL1 knockdown levels. Briefly, 50 µg of DMS-53 
lysates were loaded into 10% SDS-PAGE gels then transferred to nitrocellulose 
membranes.  Membranes were incubated with ASCL1 and β2-microglobulin 
antibodies followed by goat anti-rabbit secondary antibodies (Santa Cruz 
Biotechnology). Bands were visualized using a SuperSignal West Dura Extended 
Duration Substrate chemiluminescence kit (Pierce) and a VersaDoc Imaging 
System (Bio-Rad).   
 
3[H]-Epibatidine Binding.  Radioligand binding assays were performed in 
collaboration with Dr. Scott Roger’s laboratory (University of Utah School of 
Medicine).  SCLC cells that were transiently transfected with ASCL1 siRNA 
s1656 were harvested.  Membrane fractions were collected by centrifugation for 
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20 minutes at 20,000 x g at 4oC.  Pellets were resuspended and homogenized in 
50 mM Tris on ice.  Samples were divided into equal portions; to one set was 
added 500 µM nicotine (Sigma-Aldrich) to block all nAChRs.  Readings from 
these samples would therefore represent non-specific epibatidine binding  and 
serve as background control.  After 30 min, 3[H]-epibatidine (Perkin-Elmer) was 
added to both the nicotine-blocked and unblocked samples at a final 
concentration of 5 nM.  Membranes were incubated in a 25oC water bath for 4 
hours to ensure equilibrium was achieved.  Bound ligand was separated from 
free ligand by vacuum filtration through GF/C filters (Whatman International) 
Filters were washed with 50 mM Tris (pH 7.4).  Filters were dried completely, 
submerged in scintillation fluid and counted for retained 3[H] on a Beckman 
scintillation counter. Specific binding was calculated by averaging the total 
binding minus the background (nicotine-blocked) binding.  
 
Statistical analysis.  The mean relative expression values of each gene in the 
different samples were calculated and subjected to statistical analysis using the 
GraphPad Prism software.  Student’s t-test or one-way analysis of variance 
(ANOVA) followed by Tukey’s multiple comparison post-test was performed as 
appropriate. 
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III.C.Results 
Overexpression of the CHRNA5/A3/B4 genes in small cell lung carcinoma  
Quantitative RT-PCR was performed to compare mRNA expression of all 
known human neuronal nAChR genes across normal and lung cancer cell lines.  
Cell lines derived from each of the major lung cancer types (i.e., SCLC, large cell 
lung carcinoma, adenocarcinoma and squamous cell carcinoma) were used in 
this analysis.  Differential expression of the nAChR genes was observed across 
the different cell lines as depicted in the following heat map (Figure II-1).   
Figure II-1. Differential expression of nAChR genes across different lung 
cancer and normal cell lines. Quantitative RT-PCR was performed to 
determine mRNA levels of all human nAChR subunits.   Red boxes indicate 
high gene expression while green boxes indicate low to no gene expression.  
Samples were analyzed in triplicate. 
  
Gene expression in cancer cells relative to normal cells was then 
calculated using the 2-ΔΔCt method [293].  Two of the clustered nAChR genes, 
those encoding the α3 and β4 subunits, were significantly over-expressed in 
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SCLC lines compared to normal lung cell lines (Figure II-2).  Interestingly, 
expression of the α5 subunit gene was high in all the cell lines studied, including 
normal lung cell lines, with no significant differences in α5 expression observed 
in any of the cell lines.  Conversely, the α3 and β4 subunits had low expression 
in large cell, adenocarcinoma and squamous cell carcinoma lines, similar to that 
in normal lung cell lines.  
 
Figure II-2. Over-expression of the nAChR α3 and β4 genes across different 
cell lines.  The 2-ΔΔCt method was used to compared expression levels of the 
CHRNA5/A3/B4 genes in cancer cell lines compared to normal lung cell lines. 
The line within each box represents the median fold change relative to normal.  
The upper and lower edges of each box represent the 75th and 25th percentiles 
whereas the upper and lower bars represent the maximum and minimum 
values, respectively.  * p < 0.05, *** p < 0.001; n=3; ANOVA-Tukey. 
 
With respect to the non-clustered nAChR subunit genes, the α4, α7, α10, 
and β2 genes were also significantly over-expressed in SCLC compared to 
normal lung cell lines (Figure II-3, see following page).  In addition, the α7 gene 
was significantly over-expressed in large cell carcinoma cell lines. 
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Figure II-3. Differential expression of the nAChR α2, α4, α6, α7, α9, α10, β2, 
and β3 genes across different lung cell lines. The 2-ΔΔCt method was used to 
compared expression levels of nAChR genes in cancer cell lines compared to 
normal lung cell lines. The line within each box represents the median fold 
change relative to normal.  The upper and lower edges of each box represent 
the 75th and 25th percentiles whereas the upper and lower bars represent the 
maximum and minimum values, respectively.  * p < 0.05, ** p < 0.01, *** p < 
0.001; n=3; ANOVA-Tukey.  
 
Using a more physiologically relevant approach, we analyzed mRNA 
expression of the same set of genes in normal and lung cancer patient samples.  
The samples were from patients with SCLC, large cell lung carcinoma, 
adenocarcinoma and squamous cell carcinoma.  Expression of all of the nAChR 
subunit genes was low in normal lung tissue.  In comparison, all three of the 
clustered nAChR genes were significantly over-expressed in SCLC (Figure II-4).  
The α5 subunit gene was also significantly over-expressed in all NSCLC samples 
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(Figure II-4B) while the β4 subunit gene was significantly over-expressed in 
adenocarcinoma and squamous cell carcinomas (Figure II-4C). 
 
 
Figure II-4. Over-expression of the nAChR α3, α5, and β4 genes in lung 
cancer patient samples. The 2-ΔΔCt method was used to compared expression 
levels of nAChR genes in cancer cell lines compared to normal lung cell lines. 
The line within each box represents the median fold change relative to 
normal.  The upper and lower edges of each box represent the 75th and 25th 
percentiles whereas the upper and lower bars represent the maximum and 
minimum values, respectively. ** = p < 0.01, *** = p < 0.001; n =3; ANOVA-
Tukey. 
 
 
In SCLC samples, the nAChR α9 and β2 subunit genes were significantly 
over-expressed compared to normal lung tissue (Figure II-5E and G).  With 
respect to non-small cell lung cancer, the β2 subunit gene was significantly over-
expressed in adenocarcinoma and squamous cell carcinoma (Figure II-5G). In 
contrast, nAChR α2 subunit gene expression was significantly lower in all lung 
cancer tissues compared to normal lung tissue (Figure II-5A).  
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Figure II-5. Differential expression of the nAChR α2, α4, α6, α7, α9, α10, β2, 
and β3 genes across different lung cancer patient samples. . The 2-ΔΔCt method 
was used to compared expression levels of nAChR genes in cancer cell lines 
compared to normal lung cell lines. The line within each box represents the 
median fold change relative to normal.  The upper and lower edges of each box 
represent the 75th and 25th percentiles whereas the upper and lower bars 
represent the maximum and minimum values, respectively * = p < 0.05, ** = p < 
0.01, *** = p < 0.001; n=3; ANOVA-Tukey. 
 
 
E-boxes are present in the promoters of the clustered nicotinic receptor genes 
The high expression of the α3, α5, and β4 genes in SCLC as well as their 
genomic clustering suggests that they may be coordinately regulated [168].  As 
an initial approach to identifying regulatory factors of this gene locus, we 
analyzed the promoter region of each gene for potential transcription factor 
binding sites.  A number of putative binding sites for basic helix-loop-helix 
transcription factors were identified (Figure II-6).   
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Figure II-6.  The CHRNA5/A3/B4 gene cluster contains putative ASCL1 binding 
sites.  E-boxes (yellow), containing the consensus sequence CANNTG, are 
present in the promoter regions of the α5, α3, and β4 genes (orange, blue, and 
green boxes, respectively).  Straight arrows indicate the directions of 
transcription while bent arrows indicate major transcription initiation sites.  
 
These sites are referred to as E-boxes and have the core sequence 5'-
CANNTG-3'.  The α3 gene promoter contains two E-boxes with the sequences 
CAGGTG and CACCTG.  The α5 gene promoter contains four E-boxes with the 
sequences CAAATG, CAGCTG, CACCTG, and CACATG while the β4 gene 
promoter contains five E-boxes with the sequences CATTTG, CACATG, 
CAGCTG, and two CAGGTGs.  With the exception of one E-box in the β4 
promoter, all E-boxes are located upstream of reported major transcription 
initiation sites [196, 219, 294]. 
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ASCL1 regulates expression of the clustered nicotinic receptor genes 
Although there is a large family of basic helix-loop-helix transcription 
factors, we focused on ASCL1 because of its critical role in SCLC, as described 
above.  To determine whether ASCL1 regulates expression of nicotinic receptor 
genes, knockdown experiments were done in SCLC cell lines using small 
interfering RNAs (siRNAs) against ASCL1.  To control for off-target effects, three 
distinct siRNAs were used.  The most potent siRNA, s1656, reduced ASCL1 
mRNA expression by approximately 87% leading to an 89% decrease in α3 gene 
expression, a 45% decrease in α5 gene expression and a 78% decrease in β4 
gene expression (Figure II-7A, left).  The second siRNA, s1657, reduced ASCL1 
mRNA expression by 64% leading to a 77% decrease in α3 gene expression, an 
18% decrease in α5 gene expression and a 66% decrease in β4 gene 
expression (Figure II-7A, middle).  The third siRNA, s1658, reduced ASCL1 
mRNA expression by 65% leading to a 78% decrease in α3 gene expression, a 
17% decrease in α5 gene expression and a 41% decrease in β4 gene 
expression (Figure II-7A, right).  Decreases in α5 expression were not found to 
be statistically significant.  In addition, ASCL1 knockdown did not significantly 
affect the expression of the genes encoding the α7 and β2 subunit genes, two 
other nAChR subunits implicated in lung cancer, indicating specificity of α3 and 
β4 subunit gene regulation by ASCL1.  ASCL1 knockdown also did not affect the 
expression of the housekeeping gene, GAPDH (data not shown).  Furthermore, 
knockdown of ASCL1 in a non-small cell lung carcinoma cell line, A549, did not 
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reduce expression of the α3, α5, and β4 subunit genes (Figure II-7B).  
Expression of the β2 subunit gene, however, appears to increase in this cell line 
upon ASCL1 knockdown.  
 
 
Figure II-7.  Knockdown of ASCL1 leads to a decrease in CHRNA3/B4 gene 
expression in SCLC but not NSCLC.  ASCL1 knockdown was achieved in 
SCLC (A) and NSCLC (B) cells using three different siRNAs: s1656, s1657, 
and s1658.  Changes in gene expression were determined using quantitative 
RT-PCR.  Samples treated with a negative control siRNA (white boxes) were 
used as calibrator (i.e., expression levels for these samples was set at 1).  
Error bars indicate SEMs. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, 
compared to negative control; n = 4; ANOVA-Tukey. 
 
Western blot analysis confirmed that ASCL1 knockdown was achieved at 
the protein level using all three siRNAs (Figure II-8A).  Furthermore, 3[H]-
epibatidine-binding assays show that ASCL1 knockdown leads to a decrease in 
the total amount of nAChR binding sites on the cell membrane (Figure II-8B).  
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Figure II-8.  Total nAChR binding sites decrease upon ASCL1 knockdown. A. 
Western blot analysis shows decrease in ASCL1 protein expression upon 
treatment with ASCL1 s1656, s1657, and s1658 siRNAs (top, middle, and 
bottom panels, respectively). Lane 1: No ASCL1 primary antibody; Lane 2: 
Untreated SCLC cells; Lane 3: Negative control siRNA-treated cells; and Lane 
4: ASCL1 siRNA-treated cells. β2-microglobulin (β2M) was used as loading 
control. B. A radioligand-binding assay was performed using epibatidine, a 
nAChR ligand, to determine total nAChR levels at the cell surface upon ASCL1 
siRNA treatment. Error bars indicate SEMs. * = p < 0.05, n=3, Student’s t-test. 
 
III.C.Discussion 
Our observation that the nAChR α3, α5 and β4 subunit genes are over-
expressed in SCLC is particularly intriguing in light of the recent genome wide 
association studies implicating the CHNRA5/A3/B4 gene locus in lung cancer 
susceptibility [267-269, 281].  Over-expression of the clustered nAChR genes in 
lung cancer cells supports the notion that these genes play a role independent of 
A B 
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the nicotine addiction pathway.  Extrapolating on data gained from work in the 
nervous system and our own observations, the possible nAChR subtypes that 
can form in SCLC include α3β2, α3β4, α3β4α5, and α3β2β4α5 [22].  These 
subtypes are believed to be involved in ganglionic neurotransmission in the 
peripheral nervous system [295].  A thorough investigation of functional nAChR 
subtypes in lung cancer has yet to be done but there is evidence that specific 
subtypes mediate distinct processes. For example, α3-containing nAChR 
subtypes have been implicated in nicotine-mediated activation of the Akt pathway 
[136] whereas the α7 subtype is thought to mediate nicotine-induced 
angiogenesis and NNK-induced apoptotic inhibition [136, 296].  α7 nAChRs also 
have high calcium permeability and binding of NNK results in calcium influx, 
which triggers signaling pathways that result in cell proliferation, increased cell 
migration, apoptotic inhibition, and angiogenesis [280].     These two examples 
indicate the need to identify all of the precise nAChR subtypes in lung cancer 
cells as this may be important for design of targeted therapeutics given the 
unique pharmacological and functional properties of each nAChR subtype. 
 
As nAChRs are the cognate receptors for nicotine and NNK, their 
activation is likely the first step in signal transduction cascades involving these 
ligands.  Persistent activation of cancer-promoting pathways has been shown to 
result from nicotine and NNK exposure and may facilitate SCLC development 
[128, 297].  While these pathways remain to be completely elucidated, they 
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appear to involve the mitogen activated kinases ERK1 and ERK2, protein kinase 
C (PKC), the serine/threonine kinase RAF1 and the transcription factors FOS, 
JUN and MYC [280].  In addition, exposure to nicotine has also been shown to 
reduce the efficacy of anti-cancer agents by inhibiting apoptosis [114].  
Pharmacological approaches suggest that these effects are mediated at least in 
part by homomeric α7 nAChRs [280] but the role of other nAChR subtypes 
cannot be ruled out due to the lack of specificity of currently available 
pharmacological agents. 
 
That nAChRs may function in SCLC is not totally unexpected given their 
important role in the nervous system.  SCLC is believed to develop from 
pulmonary neuroendocrine cells.  As the name suggests, these cells share 
properties with neurons such as the expression of ion channels and 
neuropeptides and have been referred to as paraneurons [298]. 
 
From a regulatory standpoint, the over-expression of the clustered nAChR 
genes also yields some interesting insights.  Several laboratories have previously 
identified regulatory features shared by these genes [211, 212, 214, 215, 219, 
221, 232, 242, 243].  Based on these studies, it is believed that expression of the 
clustered nAChR genes results from interactions between ubiquitously expressed 
and cell-type-specific transcription factors with cis-acting regulatory elements 
located within or near the cluster.  To date, only one cell-type-specific factor, 
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Sox10, has been identified and shown to regulate nAChR gene expression [218, 
226].  Sox10 activates the promoters of the clustered genes in neuronal cell lines 
but not in non-neuronal cells.  However, we have observed that Sox10 is not 
expressed in any of the lung cancer cell lines we used in this study (data not 
shown).  This suggests that other transcription factors must be involved in the 
expression of nAChR genes in lung cancer.  As mentioned above, the 
transcription factor ASCL1 is an interesting candidate given its role in SCLC 
[289-292].  ASCL1 is also known to activate neuroendocrine differentiation 
markers while suppressing putative tumor suppressor genes [299].  In addition, 
ASCL1 is required for the proper development of peripheral sympathoadrenal 
tissues, the same tissues where the clustered nAChR genes are abundantly 
expressed [300]. 
 
The knockdown experiments presented here indicate that ASCL1 robustly 
regulates the expression of the α3 and β4 genes while α5 gene expression was, 
at most, modestly affected.  These regulatory differences are likely due to the 
fact that each gene has its own promoter.  Hence, although the three genes 
share common regulatory elements, each gene may have additional mechanisms 
that allow fine-tuning of its specific expression.  Moreover, the α5 gene is 
transcribed in the opposite direction as the α3 and β4 genes raising the 
possibility that transcription factors that bind to the α3 and β4 promoters may be 
differentially utilized by the α5 promoter and vice versa.  Nevertheless, the effect 
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of ASCL1 on nAChR subunit gene expression in SCLC appears to be specific for 
the clustered subunit genes, as expression of the α7 and β2 genes was not 
affected by ASCL1 knockdown.  In contrast, ASCL1 knockdown does not reduce 
the expression of the clustered subunit genes in NSCLC whereas it increases the 
expression of the β2 gene, suggesting cell-type specificity of ASCL1 regulation. 
 
Control of nAChR gene expression by ASCL1 may provide a mechanism 
for the role of nicotine in lung cancer.  Nicotine has been shown to induce cellular 
processes that may lead to the development of cancer including activation of cell 
proliferation and survival pathways [280].  Acetylcholine, the endogenous ligand 
for nAChRs, is also thought to act as an autocrine growth factor in lung cancer 
cells [301].  Over-expression of their cognate receptors via transcriptional control 
by ASCL1 may thereby potentiate the effects of these ligands, providing a 
mechanism by which cigarette smoking can promote the growth and 
aggressiveness of SCLC. 
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CHAPTER III:  
α5-CONTAINING NICOTINIC ACETYLCHOLINE RECEPTORS MEDIATE 
SCLC TUMOR GROWTH 
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I have had my results for a long time:  but I do not yet know how I am to arrive at 
them. 
- Carl Friedrich Gauss 
 
III.A.Introduction 
 
Lung cancer is the most frequent cause of cancer deaths, causing over a 
million deaths annually [5].  Clinically and histopathologically, lung cancer is 
divided into two groups: non-small cell lung carcinoma (NSCLC) and small cell 
lung carcinoma (SCLC).  NSCLC consists of a heterogenous group of tumors 
that account for 80% of lung cancer cases [302].  SCLC is a highly malignant 
form of lung cancer, thought to arise from primitive neuroendocrine cells [303]. 
Though SCLC is more rare, it is characterized by unfavorable prognostic factors 
such as early and widespread metastases, chemoresistance, and relapses [304]. 
 
Tobacco use is the major risk factor associated with lung cancer.  
Research through the years has forged connections between nicotine in tobacco 
and various cancer-related events such as cell proliferation, apoptotic inhibition, 
angiogenesis, and metastasis [115, 305].  Nicotine acts through its cognate 
receptors, nicotinic acetylcholine receptors (nAChRs), for which acetylcholine is 
the endogenous ligand.  nAChRs are pentameric, ligand-gated ion channels 
assembled from homozygous or heterozygous combinations of α and β subunits 
[306].  To date, eleven genes have been identified encoding human nAChR 
subunits (α2-α10 and β2-β4).   
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Linkage and association studies have implicated the genes encoding the 
α3, α5, and β4 nAChR subunits in lung cancer etiology [167, 267, 269].  These 
genes encode nAChR subunits that frequently co-assemble.  The three genes lie 
in a cluster in chromosome 15q25 and harbor single nucleotide polymorphisms 
(SNPs) that increase risk for developing both nicotine dependence and lung 
cancer.  Of particular interest is a non-synonymous SNP (rs16969968) in the 
CHRNA5 gene that decreases protein function in heterologous systems [258, 
307].  It is unclear if the genetic association with lung cancer is simply a reflection 
of higher levels of nicotine dependence in carriers of risk alleles and 
consequently greater exposure to tobacco carcinogens [274].  A case for direct 
association, however, is supported by studies showing increased risk in never-
smokers and in smoking populations after adjustment for smoking behaviors 
[272, 308].  Furthermore, the polymorphism is not associated with other smoking-
related cancers such as head and neck cancers (e.g., cancers of the mouth, 
larynx, pharynx, and esophagus) [267].  
 
We sought to address this quandary by directly investigating the role of 
the CHRNA5/A3/B4 genes in lung cancer.  We have previously shown that these 
genes are expressed at aberrantly high levels in SCLC [309].  Here, we 
demonstrate that CHRNA5/A3/B4 depletion leads to a decrease in SCLC cell 
viability.  In addition, we show that nicotine treatment increases cell viability while 
treatment with α-conotoxin AuIB, a selective antagonist of α3β4 nAChRs [310], 
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decreases cell viability.  Using a xenograft tumor model, we also show that 
nicotine promotes tumor growth while CHRNA5 silencing inhibits tumor growth in 
vivo.   
 
III.B.Materials and Methods 
siRNA knockdown.  Cells were seeded in black, clear bottom 96-well assay 
plates and allowed to grow overnight.  Cells were transiently transfected using 
Lipofectamine 2000 (Invitrogen) in Opti-MEM (Invitrogen) with 10 nM of a 
Silencer Select Negative Control #1 or CHRNA3 (s3043, s3044, s3045), 
CHRNA5 (s3049, s3050, s3051), and CHRNB4 (s3064, s3065, s3066) siRNAs 
(Applied Biosystems).  After 48 hours, cells were harvested and subjected to a 
bioluminescence-based cell viability assay (described in detail in Chapter IV.B).  
To determine knockdown efficiency, cells were seeded in parallel onto 6-well 
cluster plates and transfected as above.  After 48 hours, cells were harvested 
and total RNA was isolated using an RNeasy Mini Kit (Qiagen).  RNA was 
reverse-transcribed using RETROscript reagents (Applied Biosystems).  
Samples without reverse transcriptase were used as negative controls. 
CHRNA5/A3/B4 transcripts were amplified using Applied Biosystems TaqMan 
assays (Hs00181248_m1, Hs00609519_m1, and Hs00609523_m1, respectively) 
and the PRISM 7500 real-time PCR system (Applied Biosystems).  Gene 
expression was quantified using the 2-ΔΔCt method [293].  β2-microglobulin 
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(Hs00187842_m1) was used as the endogenous control to normalize gene 
expression levels. 
 
Drug Treatment.  DMS-53 cells were seeded onto black, clear bottom 96-well 
assay plates and allowed to grow overnight.  Cells were then treated daily for one 
week with the 1 µM nicotine (Sigma-Aldrich) or 2 µM α-conotoxin AuIB (a gift 
from J. Michael McIntosh, University of Utah School of Medicine). Cells were 
then harvested and subjected to a bioluminescence-based cell viability assay.    
 
CHRNA5 Gene Sequencing.  DMS-53 cells were grown in a 10-cm plate and 
harvested.  Genomic DNA was isolated from the cells using a Qiagen DNeasy 
Kit.  A region of CHRNA5 containing the rs16969968 SNP was then amplified 
using the following primers: Forward - 5’-CCATCATCTTCAAAAGTCATACCTC-
3’ and Reverse - 5’-AGTTCACCCACTGCCCTCAC-3’.  PCR was carried out with 
Phusion High-Fidelity DNA polymerase (Finnzymes/Thermo-Scientific) using the 
following thermal cycling parameters: 98oC for 3 min; 35 cycles of 98oC for 10 
sec, 67oC for 30 sec, 72oC for 25 sec; and 72oC for 3 min. PCR products were 
then purified using a Qiaquick PCR purification kit (Quiagen) and sent out for 
direct sequencing (Genewiz).  Sequences were analyzed using Sequence 
Scanner Software (Applied Biosystems). 
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shRNA knockdown.  Two lentiviral pGIPZ CHRNA5 shRNAmir constructs (Open 
Biosystems; CHRNA5 A Clone ID: V3LHS_367770; CHRNA5 B Clone ID: 
V3LHS_367772) were used to transfect HEK293T cells for viral packaging using 
the Trans-Lentiviral Packaging System (Open Biosystems). A non-silencing 
shRNAmir (Open Biosystems) was used as a negative control (this control is 
processed by the endogenous RNA interference pathway but the processed 
siRNA does not target any RNA in the mammalian genome).  Viral particles were 
harvested and used to transduce SCLC cells in the presence of 4 µg/ml 
polybrene (Sigma).  To select for cells stably expressing the shRNAmirs, cells 
were treated with 6 µg/ml puromycin dihydrochloride for 5 days. 
 
Xenograft Tumor Model. All animal experiments were conducted in accordance 
with the guidelines for care and use of laboratory animals provided by the 
National Research Council [311] as well as with an approved animal protocol 
from the Institutional Animal Care and Use Committee of the University of 
Massachusetts Medical School (Assurance Number A-3306-01).  DMS-53 cells 
supplemented with Matrigel (BD Biosciences) were implanted subcutaneously 
onto the hind flanks of 6-week old athymic nude mice (Charles River 
Laboratories). After 60 days, tumors were harvested and weighed.  Tumor size 
was determined by measuring the length and width of tumors at the longest axes 
using a digital caliper. To measure CHRNA5 knockdown levels, total RNA was 
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isolated from representative samples and quantitative RT-PCR was performed as 
described above. 
  
Chronic Nicotine Treatment via Minipumps.  Athymic nude mice carrying tumor 
xenografts were implanted subcutaneously with osmotic minimpumps (Alzet).  
Mice were anesthetized using ketamine/xylazine before minipump implantation.  
Minipumps delivered either saline or 24 mg/kg/day of nicotine (Sigma-Aldrich) at 
a rate of 0.25 µl per hour and last for about a month.  After one month, tumors 
were harvested, measured for size, and weighed.  
 
III.C.Results 
To determine the role of CHRNA5/A3/B4 in SCLC, we silenced the expression of 
these three genes in the SCLC cell line, DMS-53. Three distinct siRNAs against 
each gene in the cluster were used. Treatment with CHRNA3 a, b, and c resulted 
in 97%, 97%, and 93% decrease in mRNA levels, respectively; treatment with 
CHRNA5 a, b, and c resulted in 71%, 93%, and 77% decrease in mRNA levels, 
respectively; and treatment with CHRNB4 a, b, and c resulted in 96%, 91%, and 
95% decrease in mRNA levels, respectively (Figure III-2A).  Using a 
bioluminescence-based viability assay, we found that all siRNAs that yielded 
>90% knockdown also significantly decreased SCLC cell viability (Figure III-2B).  
Interestingly, the two siRNAs that yielded the least knockdown levels, CHRNA5 a 
 64 
and c, did not significantly affect cell viability, suggesting that certain CHRNA5 
depletion levels may need to be reached to obtain an observable phenotype. 
  
 
 
Figure III-1.  CHRA5/A3/B4 depletion decreases viability of SCLC cells.  
SCLC cells were treated with negative control or CHRNA5/A3/B4 siRNAs. A. 
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qRT-PCR was performed to determine mRNA levels upon knockdown.  B. A 
cell viability assay was performed to determine the effect of siRNA treatment 
on SCLC cell viability (*** = p value < 0.01; n = 3 for quantitative RT-PCR, n = 
5 for viability assay; ANOVA-Tukey. 
 
 
Using the same bioluminescence-based assay, we then tested the effect 
of nAChR ligands on SCLC cell viability.  Nicotine treatment increased SCLC cell 
viability (Figure III-2).  Notably, treatment with the α3β4 nAChR-selective 
antagonist, α-conotoxin AuIB, showed the opposite effect (i.e., blocking α3β4-
containing nAChRs decreased SCLC cell viability). 
 
 
Figure III-2.  Exposure to nAChR ligands regulates SCLC cell viability.  DMS-
53 cells were treated daily for 1 week with 1 µM nicotine (nAChR agonist) or 2 
µM a-conotoxin AuIB (α3β4 nAChR antagonist).  Cell viability was then 
measured.  Values were normalized to those of saline-treated samples.  
Asterisks indicate statistical significance compared to saline controls (* = p 
value < 0.05, ** = p value < 0.01; n = 5; one way ANOVA followed by Tukey’s 
multiple comparison post-test). 
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For in vivo propagation of tumors, we utilized the tumor xenograft model.  
We focused on CHRNA5 as it harbors the non-synonymous SNP, rs16969968.  
To determine the rs16969968 allele status of the SCLC cell line, DMS-53, used 
in the xenograft assays, we directly sequenced the CHRNA5 region containing 
this SNP.  The following chromatograms show that this cell line is heterozygous 
at this locus. 
 
 
Figure III-1.  Forward and reverse sequence chromatograms of the 
rs16060068 locus. Genomic DNA was isolated from the SCLC cell line, DMS-
53.  The CHRNA5 exon 5 region containing the rs16969968 SNP was PCR 
amplified and sequenced.  Arrows indicate the double A/G (T/C) peaks, 
indicating heterozygosity at this locus. 
 
 
 
This cell line was used to stably express two distinct CHRNA5 shRNAmirs via 
lentiviral delivery. Cells were then implanted subcutaneously into 
immunodeficient mice and allowed to grow.  The cells were supplemented with 
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Matrigel to provide the complex extracellular environment found in many tumors.  
After tumors were harvested, CHRNA5 knockdown levels were determined. 
 
  
Figure III-4. CHRNA5 depletion inhibits growth of tumor xenografts. DMS-53 
cells stably expressing CHRNA5 shRNAmirs were subcutaneously injected 
into the hind flanks of immunocompromised mice A. CHRNA5 shRNAmir A 
and B knockdown levels in harvested tumors.  B.  Representative tumor 
images. C-D. Tumor sizes and weights, respectively. * = p < 0.05, ** = p < 
0.01; n = 9 for non-silencing, n = 5 for CHRNA5 shRNAmir A, n = 9 for 
CHRNA5 shRNAmir B; ANOVA –Tukey. 
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Treatment with CHRNA5 shRNAmir A resulted in a 59% decrease in mRNA 
levels while treatment with CHRNA5 shRNAmir B resulted in a 66% decrease in 
mRNA levels (Figure III-4A).  CHRNA5 knockdown led to a decrease in tumor 
size and weight (Figure III-4B-D), suggesting that CHRNA5 is important for SCLC 
tumor growth.  In addition, while all cells treated with the non-silencing shRNAmir 
formed tumors, two out of the nine samples treated with CHRNA5 shRNAmir B 
did not form tumors, suggesting that CHRNA5 may also impact rates of tumor 
incidence. 
 
Finally, we tested the effect of chronic nicotine treatment on the growth of SCLC 
tumors in vivo.  We used osmotic minipumps to deliver nicotine as these devices 
allow continuous dosing of drugs, while eliminating repeated injections and 
minimizing animal handling.  This treatment paradigm has not been previously 
used to test the effect of nicotine on tumor growth.  As shown in Figure III-5, 
chronic nicotine exposure promotes the growth of tumors compared to saline-
treated mice. 
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Figure III-5. Chronic nicotine exposure increases SCLC tumor growth. A. 
SCLC cells were injected subcutaneously onto the hind flanks of athymic 
nude mice. Mice were then implanted with osmotic minipumps to deliver 
either saline (top panel) or 24 mg/kg/day of nicotine (bottom panel).  After 4 
weeks, tumors were harvested and tumor size (B) and weights (C) were 
measured.  ** = p < 0.01; n = 4; Student’s t-test.   
 
 
III.D.  Discussion 
Our findings that CHRNA5/A3/B4 depletion inhibits SCLC cell viability provide 
mechanistic support to the correlative link between these genes and lung cancer 
susceptibility.  It suggests that the clustered genes perform a vital function in the 
maintenance of SCLC cell viability.  That the CHRNA5/A3/B4 genes play a role in 
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lung cancer, outside of their role in nicotine addiction, attests to the pleiotropic 
function of these genes. 
 
Consistent with our genetic approach, we found that pharmacological activation 
and blockade of α5α3β4 nAChRs modulates SCLC cell viability. Treatment with 
nicotine promotes SCLC cell viability, in line with previous findings on the 
proliferative effect of nicotine on SCLC cells [116, 117, 134].  This result 
suggests the presence of functional nAChRs in DMS-53 cells and confirms its 
suitability for the experiments described in this study.  This result also verifies the 
reliability of our bioluminescence viability assay as a tool for studying the effects 
of genetic and pharmacological agents against SCLC.   
 
To perform the converse experiment, we utilized the α3β4-selective 
ligand, α-conotoxin AuIB.  α-conotoxins are derived from the venom of 
carnivorous cone snails, which have proved to be a valuable source for disulfide-
bonded peptides that target nAChRs in a highly subtype-selective manner.  α-
conotoxin AuIB, in particular, was isolated from the snail-eating cone Conus 
aurilicus and blocks α3β4 nAChRs with > 100-fold higher potency than other 
nAChR subtypes [310].  Treatment with α-conotoxin AuIB leads to decreased 
viability of DMS-53 cells, indicating that functional α3β4 nAChRs are present in 
SCLC cells and are important for maintenance of SCLC cell viability.  The 
unavailability of selective α5α3β4 nAChR ligands limits our ability to determine 
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the role of this subtype in SCLC cell viability.  Nevertheless, the co-expression of 
CHRNA5/A3/B4 in DMS-53 cells and the proclivity of α3β4 nAChRs to form 
mature receptors with α5, suggests that the observed reduction in cell viability is 
due in part to blockade of α5α3β4 nAChRs. 
 
We next turned to the xenograft tumor model, one of the most commonly 
used mouse models for studying cancer, for a more physiologically relevant 
approach.  The key advantages of this model include 1) the use of actual human 
cells, containing the genetic and epigenetic peculiarities of human samples; 2) 
availability of results within a couple of months; and 3) its relative ease and 
simplicity [312].  We focused on CHRNA5 given the presence in its coding region 
of the only non-synonymous SNP associated with both nicotine dependence and 
lung cancer.  CHRNA5 knockdown in this cell line decreased tumor growth and 
incidence, indicating the importance of CHRNA5 in these processes. 
 
Sequence analysis revealed the heterozygous nature of rs16969968 in 
DMS-53 cells.  Since CHRNA5 shRNAmirs decrease levels of total CHRNA5 
mRNA, our results illustrate the effect of decreasing both allelic versions.  Hence, 
we cannot infer from our data whether the reduction in tumor growth is the effect 
of a reduction in a specific allele or the effect of a global loss of CHRNA5.   
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It is also worth noting that the knockdown levels achieved using the 
shRNAmirs were not as robust as those seen using the siRNAs.  However, 
shRNAmirs are stably expressed due to their integration into the genome.  This 
relatively low but stable knockdown appears to be sufficient to yield a 
measurable phenotype. 
 
In conclusion, our results indicate a role for the CHNRA5/A3/B4 genes in SCLC 
and supports the hypothesis that allelic variations in these genes are directly 
associated with lung cancer susceptibility.  The added association with nicotine 
dependence suggests a mechanism for exacerbation of risk (a double whammy 
effect), possibly providing an explanation for the tight linkage between tobacco 
use and SCLC [10].  Moreover, association with other diseases such as 
alcoholism, COPD, and peripheral arterial disease [268, 275, 276] suggests 
pleiotropy at this locus and warrants further investigation into the role of the 
CHRNA5/A3/B4 genes in other pathological states.  Finally, inhibition of cell 
viability and tumor growth by genetic and pharmacological disruption of 
CHNRA5/A3/B4 suggests the utility of these genes as therapeutic targets for 
SCLC.   
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CHAPTER IV:  
HIGH-THROUGHPUT SCREEN IDENTIFIES PHARMACOLOGICAL AGENTS 
THAT TARGET NEUROTRANSMITTER SIGNALING IN SCLC 
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We have two options, medically and emotionally: give up or fight like hell. 
- Lance Armstrong 
IV.A.Introduction 
Lung cancer is the leading cause of cancer-related mortality worldwide, 
resulting in over 1.3 million deaths per year [5]. In the United States, lung cancer 
incidence rates are second only to rates for breast cancer in females and 
prostate cancer in males [6].  Tobacco use is the major risk factor associated 
with lung cancer.  Histopathological classification divides lung cancer into two 
main types:  small cell lung carcinoma (SCLC) and non-small cell lung carcinoma 
(NSCLC).  NSCLC can be further subdivided into adenocarcinoma, squamous 
cell, and large cell lung carcinoma. 
 
SCLC is the most aggressive type of lung cancer, as demonstrated by its 
rapid doubling time and early development of widespread metastases [313].  In 
fact, SCLC is so aggressive that by the time it is diagnosed, metastasis has 
usually already occurred such that surgical resection of tumors is rarely an 
option. Hence, chemotherapy and radiation are the treatments of choice for these 
patients.  Most patients exhibit robust initial response to treatment but eventually 
become chemoresistant [304].  Relapses occur almost without exception and 
five-year survival rates range from 31% (for patients diagnosed at Stage I) to 2% 
(for patients diagnosed at Stage IV) [6].  Advances made in the past three 
decades have resulted in only a slight improvement in treatment outcome for 
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SCLC [314].  Identification of novel SCLC therapies is therefore of prime 
importance. 
 
Cell viability assays are indispensable tools in drug discovery efforts.  
Measurement of cell viability is a simple and rapid approach for determining a 
cell population’s response to endogenous factors such as hormones and growth 
factors as well as external stimuli such as drugs and environmental stress [315].  
A classic approach for measuring cell viability involves the use of vital dyes (e.g., 
trypan blue) for probing membrane integrity.  This method, however, is tedious 
and prone to experimenter bias [315].  Another traditional method relies on the 
reduction of tetrazolium salts such as MTT (3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide), resulting in the formation of colored products that 
can be quantified via spectrophotometry [316].  However, such assays have 
limited sensitivity, narrow dynamic ranges, and are subject to variability [315]. 
 
Bioluminescence-based assays are a favored approach due to their broad 
linearity and robustness to library compounds and complex biological samples 
[317].  These assays exploit the ability of luciferase to catalyze oxidation of a 
luciferin substrate, a reaction that generates light as a by-product [317].  Light 
generated by this reaction has the highest quantum efficiency of any known 
chemiluminescent reaction [318].  Combined with low bioluminescence signals in 
mammalian cells, this approach allows for highly sensitive assays. 
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Here, we developed a cell viability assay employing bioluminescence to 
screen for pharmacological compounds against SCLC.  From a library of 1,280 
pharmacologically active compounds, we identified several classes of drugs that 
target classic cancer signaling pathways as well as neuroendocrine markers in 
SCLC. 
 
IV.B.Materials and Methods 
Animals.  All animal experiments were conducted in accordance with the 
guidelines for care and use of laboratory animals provided by the National 
Research Council [311] as well as with an approved animal protocol from the 
Institutional Animal Care and Use Committee of the University of Massachusetts 
Medical School (Assurance Number A-3306-01).  Specifically, mice were 
exposed to 2% isofluorane before being imaged.  During imaging, mice lay on a 
temperature-regulated stage and were continually exposed to isofluorane. 
 
Cell culture.  DMS-53 and DMS-114 SCLC cell lines were acquired from the 
American Type Culture Collection (ATCC) and grown in RPMI 1640 containing L-
glutamine and 25 mM HEPES (Cellgro), supplemented with 10% fetal bovine 
serum (PAA).  HEK293T cells were acquired from Open Biosystems and grown 
in Dulbecco’s Modified Eagle’s Medium containing L-glutamine and 4.5 g/L 
glucose (Cellgro), supplemented with 10% fetal bovine serum.  Cells were 
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maintained at 37°C and 8% CO2.  Cell line authentication is performed by the 
American Type Culture Collection using cytochrome oxidase subunit I (COI) 
analysis for interspecies identification and STR analysis (DNA profiling) for 
intraspecies identification. 
 
Cloning and viral production.  A luciferase cassette was subcloned from pGL3-
Basic (Promega) into the multiple cloning site of the lentiviral expression vector 
pLEX-MCS (Open Biosystems) using SpeI and MluI (New England Biolabs) 
restriction sites. The construct, pLEX-lucSM, was transfected into HEK293T cells 
for viral packaging using the Trans-Lentiviral Packaging System (Open 
Biosystems).  Viral particles were harvested and used to transduce DMS-53 or 
DMS-114 cells in the presence of 4 µg/ml polybrene (Sigma).  To select for cells 
stably expressing luciferase (designated DMS-53 luc+ and DMS-114 luc+), cells 
were treated with 6 µg/ml puromycin dihydrochloride for 5 days. 
 
Luciferase assays.  Cells were lysed using 50 µl Reporter Lysis Buffer (Promega) 
and placed on a shaker at room temperature for 5 minutes.  To snap-freeze, cells 
were placed at -80°C for 15 minutes.  Cells were then allowed to thaw and 
equilibrate to room temperature for 15 minutes.  Plates were returned to the 
shaker for another 5 minutes before placing into a luminometer (Bio-Rad 
Lumimark).  The luminometer was set to dispense 50 µl of the luciferase 
substrate (Promega Luciferase Assay Reagent).  Integration time was set for 10 
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seconds with a 2-second lag time.  Non-luciferase expressing cells were used as 
negative controls, where indicated. 
 
MTT assay.  Cells were seeded from 0 - 1x106 cells/well in black, clear bottom 
96-well assay plates and allowed to grow overnight.  Cells were then treated with 
10 µl MTT Reagent (ATCC) and incubated for 4 hours.  After ensuring that purple 
precipitates where visible, 100 µl of Detergent Reagent (ATCC) was added.  
Samples were allowed to incubate at room temperature for another 2 hours.  
Absorbance readings at 570 nm were taken using a SpectraMax M2 microplate 
reader (Molecular Devices). 
 
Bioluminescence imaging.  For imaging of luciferase-expressing cells in vitro, 
cells were seeded onto black, clear bottom 96-well assay plates (Costar).  Before 
imaging, cell culture media were removed.  The firefly luciferase substrate D-
luciferin (Gold Biotechnology) was added at a final concentration of 150 µg/ml 
per well.  After 15 minutes of incubation, cells were imaged using a Xenogen 
IVIS 100 imager (Caliper Life Sciences), which makes use of a supercooled 
charge-coupled device (CCD) camera to detect light-emitting cells. For in vivo 
work, male athymic nude mice were obtained from Charles River Laboratories.  
For xenograft assays, cells were implanted subcutaneously onto the hind flanks 
of 6-week old mice.  For the lung colonization model, cells were injected into tail 
veins of 6-week old mice.  Mice were injected intraperitoneally with 150 mg/kg D-
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luciferin 15 minutes prior to imaging. Quantification was performed using the 
acquisition and analysis software Living Image (Caliper Life Sciences). 
 
Pharmacological treatments.  All drugs were purchased from Sigma.  For pre-
validation of the bioluminescence assay, 1x104 DMS-53 luc+ and DMS-114 luc+ 
cells were seeded in black, clear bottom 96-well assay plates and allowed to 
grow overnight.  Cells were treated with 0, 2, and 4 µM K252c (staurosporine 
aglycone) for 0, 12, and 24 hours or 0, 25, and 50 µM cis-diammineplatinum (II) 
chloride (cisplatin) for 0, 12, and 24 hours. Cells were then harvested and 
subjected to luciferase assays. 
 
RNA interference.  Cells were seeded in black, clear bottom 96-well assay plates 
and allowed to grow overnight.  Cells were transfected with 5-10 nM of a Silencer 
Select Negative Control #1 or glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) siRNA (Applied Biosystems) using Lipofectamine 2000 (Invitrogen) in 
Opti-MEM (Invitrogen).  Samples treated only with Lipofectamine 2000 were also 
used as controls.  After 48 hours, cells were harvested and subjected to 
luciferase assays.  To determine knockdown efficiency, cells were seeded in 
parallel onto 6-well cluster plates and transfected as above.  After 48 hours, cells 
were harvested and total RNA was isolated using an RNeasy Mini Kit (Qiagen).  
RNA was reverse-transcribed using RETROscript reagents (Applied 
Biosystems).  Samples without reverse transcriptase were used as negative 
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controls. GAPDH amplicons were generated using GAPDH TaqMan assays 
(Applied Biosystems) and the PRISM 7500 real-time PCR system (Applied 
Biosystems).  GAPDH levels were quantified using the 2-ΔΔCt method [293].  β2-
microglobulin was used as the endogenous control to normalize gene expression 
levels. 
 
Large-scale compound screen.  For primary screening, 5 x 104 DMS-53+ cells 
were seeded in black, clear bottom 96-well assay plates and allowed to grow 
overnight.  The following day, compounds from the Library of Pharmacologically 
Active Compounds, LOPAC1280, (Sigma) were added to each well at a final 
concentration of 50 µM in 1% dimethyl sulfoxide (DMSO).  For each plate, one 
column of cells (n=8 wells) was treated for 24 hours with equal concentrations of 
cisplatin as positive control and another column was treated with 1% DMSO as 
negative control.  Tolerance of cells for 1% DMSO was confirmed prior to 
screening (Appendix I).  Media aspiration and addition of compounds, lysis 
buffer, and luciferase substrate were performed with a Te-Mo (Tecan) automated 
system at the University of Massachusetts Medical School Small Molecule 
Screening Facility.  Luciferase readouts were taken using a Victor plate reader 
(Perkin Elmer).  For secondary screening, selected hits from the primary screen 
were retested using DMS-53 luc+ cells and further confirmed using DMS-114 
luc+ cells. For tertiary verification, DMS-53 luc+ cells were treated with increasing 
doses (0, 25, 50, and 100 µM) of the representative drugs cortexolone 
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maleate/ST-148 (Sigma) and fluoxetine hydrochloride (Sigma) for 24 hours, 
followed by luciferase assays. 
 
Analysis.  Assay quality was measured using three statistical parameters [319].  
Signal-to-background ratios (S/B) were calculated using the equation: S/B = µmax 
/µmin.  Signal-to-noise ratios (S/N) were calculated using the equation: S/N = (µmax 
– µmin)/σmin of treated controls.  For S/B and S/N, values > 2 are considered 
acceptable.  Z’-factor values were calculated using the equation Z’ factor = 1 – 
(3σmax + 3σmin)/|µmax – µmin|.  For all equations, µ represents means and 
σ represent standard deviations (SD).  For Z’-factor interpretation, we used the 
scale developed by Zhang and colleagues [320], wherein a score of 1.0 is 
considered ideal; scores between 0.5 and 1.0 represent excellent assays; scores 
between 0 and 0.5 represent marginal assays; and scores less than 0 represent 
assays that are essentially impossible to use for screening purposes. 
 
IV.C.Results 
Dose-dependent luciferase expression 
A lentiviral delivery approach was used to stably integrate a luciferase 
gene into the genome of two SCLC cell lines.  Serial dilutions of these cells were 
then prepared to determine assay sensitivity.  DMS-53 luc+ cells could be 
detected above background from as few as 10 cells using luminometry (Figure 
IV-1A).  
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Figure IV-1. Establishment of luciferase-expressing SCLC cell lines for in vitro and 
in vivo assays. A-B. Serial dilutions of DMS-53 luc+ and DMS-114 luc+ cells were 
prepared. Wells containing medium alone or 1x106 DMS-53 and DMS-114 non-
luciferase expressing cells were used as negative controls (0 cells). Cell viability 
was measured using a luminometer. C. A traditional MTT assay was performed for 
comparison of sensitivity and dynamic range. Cell viability was measured using a 
spectrophotometer. D-F. Cell viability was measured using a Xenogen IVIS 100 
imager.  Colors represent clusters of CCD pixels while color scale represents 
luminescence intensity from lowest (violet) to highest (red).  Instrument gain was 
set at min=5x107 photons/sec to max=5x108 photons/sec for DMS-53 luc+ in vitro 
(D) and at min=25x106 photons/sec to max=25x107 photons/sec for DMS-114 luc+ 
in vitro (E). For in vivo imaging (F), mice were injected subcutaneously with DMS-
53 luc+ (upper left) or DMS-114 luc+ (upper right) cells.  For the lung colonization 
model, DMS-53 luc+ (lower left) or DMS-114 luc+ (lower right) cells were injected 
into the tail vein of mice. Instrument gain was set at min=1x105 photons/sec to 
max=1x107 photons/sec for the xenograft model and at min=1x103 photons/sec to 
max=1x104 photons/sec for the lung colonization model. Columns represent mean 
values and error bars represent standard error of mean; n=5 for luminometry, n=8 
for spectrophotometry; n=4 for bioluminescence imaging. RLU - relative light units.   
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Background readings were taken from wells containing medium alone or 
wells containing 1x106 DMS-53 cells that do not express luciferase.  The linear 
range of detection for DMS-53 luc + cells was between 1x101 to 1x105 cells.  
DMS-114 luc+ cells could be detected above background from as few as 100 
cells (Figure IV-1B).  The linear range of detection for these cells was between 
1x102 to 1x105 cells.  For comparison, serial dilutions of DMS-53 luc+ cells were 
subjected to a traditional MTT assay (Figure IV-1C).  This approach required as 
many as 1x104 cells to achieve absorbance values distinguishable from 
background.  In addition, the linear range of detection for the MTT assay was 
only between 1 x104 and 1x105 cells/well.  Importantly, the MTT assay required at 
least 6 hours to run versus 45 minutes for the bioluminescence assay. 
 
An additional advantage of using bioluminescent cell lines is their direct 
applicability to in vivo bioluminescence imaging.  To confirm the utility of the 
luciferase-expressing cells for bioluminescence imaging, the Xenogen IVIS 100 
imaging system was used, wherein the number of emitted photons is proportional 
to the number of bioluminescent cells.  In vitro, the linear range of detection for 
DMS-53 luc+ was between 1x104 and 1x106 cells, yielding bioluminescence 
signals between 3x107 to 4x109 photons/sec (Figure IV-1D).  In comparison, the 
linear range of detection for DMS-114 luc+ was between 1x104 and 1x105 cells, 
yielding bioluminescence signals between 2x107 and 3x108 photons/sec (Figure 
IV-1E).  No luminescence signals could be detected in wells containing 1x106 
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DMS-53 or DMS-114 cells that did not express luciferase.  In vivo, DMS-53 luc+ 
and DMS-114 luc+ cells were used in a xenograft tumor model and a lung 
colonization model (Figure IV-1F). For the xenograft model, 1x106 DMS-53 luc+ 
and DMS-114 luc+ cells were detectable 15 minutes after injection of a luciferase 
substrate (upper left and right panels, respectively). Similarly, in the lung 
colonization model, 1x106 DMS-53 luc+ and DMS-114 luc+ cells were detectable 
in the lung area after injection of a luciferase substrate (lower left and right 
panels respectively). Mice that were implanted with cells that do not express 
luciferase did not yield luminescence signals (data not shown). 
 
Response of bioluminescent cells to pharmacological and genetic agents 
To test the hypothesis that luciferase expression reflects cell viability, we 
measured the responsiveness of the engineered SCLC cell lines to treatment 
with a known apoptosis-inducing agent, staurosporine.  DMS-53 luc+ and DMS-
114 luc+ cells were treated with staurosporine at varying doses (0, 2 and 4 µM) 
and time points (12 and 24 hours).  As shown in Figure IV-2A and IV-2B, 
luciferase activity of DMS-53 luc+ and DMS-114 luc+ cells decreased with 
increasing staurosporine concentration.  Correspondingly, luciferase activity for 
both cell lines decreased with increased exposure time (Figure IV-2C and IV-2D). 
A similar strategy was employed to determine whether the engineered cells 
would also be responsive to a known chemotherapeutic agent, cisplatin.  DMS-
53 luc+ and DMS-114 luc+ cells were treated with cisplatin at varying doses (0, 
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25 and 50 µM) and time points (12 and 24 hours).  An inverse relationship was 
observed between luciferase activity and cisplatin concentration (Figure IV-2E 
and IV-2F).  Similarly, luciferase activity decreased for both cell lines with 
increased exposure time (Figure IV-2G and IV-2H). 
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Figure IV-2.  Bioluminescent SCLC cell lines respond to pharmacological agents 
in a dose- and time-dependent manner.  DMS-53 luc+ and DMS-114 luc+ cells 
were treated with 0, 2, and 4 µM staurosporine, an apoptotic drug, for 24 hours 
(A,B) or with 4 µM staurosporine for 0, 12, and 24 hours (C,D).  DMS-53 luc+ 
and DMS-114 luc+ cells were treated with 0, 25, and 50 µM cisplatin, a 
chemotherapeutic drug, for 24 hours (E,F) and 50 µM cisplatin for 0, 12, and 24 
hours (G,H).    Luciferase assays were then performed to measure cell viability. 
Data points represent mean values and error bars represent standard error of 
means (n=5).  RLU – relative light units. 
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 Finally, to test whether the viability of the engineered SCLC cells can be 
modulated by genetic manipulation, DMS-53 cells were treated with a siRNA 
against GAPDH, a known housekeeping gene.  siRNA treatment caused a 91% 
decrease in GAPDH expression (Figure IV-3A).  GAPDH knockdown resulted in 
decreased luciferase activity (Figure IV-3B).  Taken together, these results 
indicate that the bioluminescence viability assay is a feasible assay for screening 
anti-SCLC therapies. 
 
          
 Figure IV-3.  Bioluminescent cells respond to GAPDH depletion.  A. DMS-53 
luc+ cells were treated with a siRNA against the housekeeping gene, GAPDH.  
GAPDH levels after knockdown were measured using quantitative RT-PCR.  
Approximately 91% knockdown was achieved for DMS-53 luc+.  Negative 
controls included untreated cells and cells treated with a negative control siRNA 
B. Cell viability upon GAPDH silencing was measured. *** = p < 0.001, n=3 for 
quantitative RT-PCR, n=4 for viability assay; ANOVA-Tukey. 
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High-throughput screening (HTS) of compound library 
The bioluminescence viability assay protocol was modified for 
implementation in a high-throughput setting using the DMS-53 luc+ cell line.  
Assay quality was first verified using three different statistical parameters:  S/B 
ratio, S/N ratio, and Z’-factors (see Materials and Methods).  An S/B ratio of 3.1 
and an S/N ratio of 18.6 were obtained.  Both values lie within acceptable range 
(> 2-fold).  A Z’-factor value of 0.7 was also obtained, indicating that the assay 
was excellent for screening. 
 
The assay was then used to evaluate a library of 1,280 compounds.  In 
the primary screen, numerous compounds reduced cell viability (Figure IV-4).  
Compounds that reduced cell viability at an efficiency greater than or equal to 
cisplatin (~77% reduction) were considered positive hits.  A total of 237 hits were 
identified, comprising a diverse class of compounds (Table IV-1).  The classes 
with the most number of hits ("15) included compounds directed at 
phosphorylation, dopamine signaling and serotonin signaling. 
 
Because phosphorylation is generally involved in a variety of physiological 
and pathological processes, we focused secondary screening on hits from the 
dopamine and serotonin classes of compounds.  We retested these compounds 
first using DMS-53 luc+ cells.  Of the 27 dopamine compounds, 24 were 
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confirmed during secondary screening and of the 15 serotonin compounds, 12 
were confirmed. 
Table IV-1. Classes of compounds that inhibit SCLC cell viability 
Class Number of Hits 
Adenosine 4 
Adrenoreceptor 10 
Angiogenesis 1 
Antibiotic 2 
Apoptosis 6 
Benzodiazepine 1 
Biochemistry 9 
Ca2+ Channel 10 
Cannabinoid 2 
Cell Cycle 5 
Cell Stress 2 
Cholinergic 7 
Cytokines and Growth Factors 1 
Cytoskeleton 4 
DNA Metabolism 3 
Dopamine 27 
GABA 5 
Gene Regulation 1 
Glutamate 5 
G-protein 4 
Histamine 6 
Hormone 7 
Immune System 3 
Intracellular Calcium 4 
Ion Channels 2 
Ion Pump 5 
K+ Channel 5 
Leukotriene 5 
Lipid 4 
Lipid Signaling 2 
Multi-drug Resistance 2 
Neurodegeneration 1 
Neurotransmission 7 
Nitric Oxide 4 
Opioid 5 
P2 Receptor 1 
Phosphatase 1 
Phosphorylation 39 
Serotonin 15 
Sphingolipid 1 
Tachykinin 3 
Transcription 3 
Vanilloid 2 
 Total = 237 
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Figure IV-4.  237 compounds inhibit SCLC cell viability.  DMS-53 luc+ cells were treated with compounds 
from the LOPAC1280 library.  Luciferase assays were then performed to measure the effect of the compounds 
on cell viability.  Luciferase values were normalized to the mean luciferase values of the negative control, 
DMSO (dotted line). The solid red line indicates the mean value for the positive control, cisplatin.  
Compounds that resulted in inhibition greater than or equal to that of cisplatin were considered hits. 
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To ensure that reductions in viability caused by the various compounds 
were not specific for DMS-53 luc+ cells, the confirmed compounds were retested 
using DMS-114 luc+ cells.  Of the 24 confirmed dopamine compounds, 22 
caused reduction of viability in both DMS-53 luc+ and DMS-114 luc+ cells.  Of 
the 12 confirmed serotonin compounds, all 12 reduced viability of DMS-53 luc+ 
and DMS-114 luc+ cells.  Table IV-2 lists the compounds that were effective in 
reducing viability of both cell lines along with their specific pharmacological 
actions. 
 
Finally, for tertiary verification, we performed dose-response assays of two 
representative compounds, one from each class.  As shown in Figure IV-5A, 
treatment of DMS-53 luc+ cells with increasing doses of cortexolone maleate, a 
D2 dopamine receptor antagonist, resulted in corresponding decreases in cell 
viability.  Similarly, increasing concentrations of fluoxetine hydrochloride, a 
serotonin uptake inhibitor, resulted in corresponding decreases in cell viability 
(Figure IV-5B). 
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Table IV-2. Pharmacological agents that target neurotransmitter signaling in SCLC 
Class Name Action Selectivity 
BP 897 Agonist D3 
Chlorprothixene hydrochloride Antagonist D2 
Cortexolone maleate* Antagonist D2 
(±)-Butaclamol hydrochloride Antagonist D2>D1 
R(+)-6-Bromo-APB hydrobromide Agonist D1 
BTCP hydrochloride Blocker Reuptake 
Chlorpromazine hydrochloride Antagonist - 
R(-)-N-Allylnorapomorphine hydrobromide Agonist - 
Dihydroergocristine methanesulfonate Agonist - 
R(-)-Propylnorapomorphine hydrochloride Agonist D2 
R(-)-2,10,11-Trihydroxyaporphine hybrobromide Agonist D2 
GBR-12909 dihydrochloride Inhibitor Reuptake 
R(-)-2,10,11-Trihydroxy-N-propylnoraporphine 
hydrobromide 
Agonist D2 
Fluspirilene Antagonist D2/D1 
cis-(Z)-Flupenthixol dihydrochloride Antagonist - 
Fluphenazine dihydrochloride Antagonist D1/D2 
GBR-12935 dihydrochloride Inhibitor Reuptake 
(±)-Octoclothepin maleate Antagonist D2 
Perphenazine Antagonist D2 
Pimozide Antagonist D2 
Prochlorperazine dimaleate Antagonist - 
Dopamine 
Thiothixene hydrochloride Antagonist D1/D2 
Amperozide hydrochloride Ligand - 
Paroxetine hydrochloride hemihydrate Inhibitor Reuptake 
CGS-12066A maleate Agonist 5-HT1B 
S-(+)-Fluoxetine hydrochloride Inhibitor Reuptake 
Fluoxetine hydrochloride* Inhibitor Reuptake 
SB 228357 Antagonist 5-HT2B/2C 
Metergoline Antagonist 5-HT2/5-
HT1D 
GR 127935 hydrochloride hydrate Antagonist 5-HT1B/1D 
Sertraline hydrochloride Inhibitor Reuptake 
Parthenolide Inhibitor - 
Ritanserin Antagonist 5-HT2/5-
HT1C 
Serotonin 
SB 224289 hydrochloride Antagonist 5-HT1B 
* Representative drugs tested for tertiary verification 
- Unknown selectivity 
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Figure IV-5.  SCLC cells respond to cortexolone maleate and fluoxetine 
hydrochloride in a dose-dependent manner. DMS-53 luc+ cells were treated 
with 0, 25, 50, and 100 µM cortexolone maleate (A) or fluoxetine hydrochloride 
(C,D) for 24 hours. Luciferase assays were then performed to measure cell 
viability. Data points represent mean values and error bars represent standard 
error of means (n=8).  RLU – relative light units. 
 
 
DISCUSSION 
With the aim of uncovering novel therapeutic strategies against SCLC, we 
developed a bioluminescence-based cell viability assay for high-throughput 
screening of compound libraries.  Phenotypic assays such as the one described 
here expedite primary screening of large numbers of chemicals, while limiting the 
use of animals in research.  In this study, we used two cell lines, DMS-53 luc+ 
and DMS-114 luc+, that were originally derived from mediastinal biopsies of 
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SCLC patients who had not received prior therapy, allowing delineation of 
specific effects of novel compounds [321].  
 
We demonstrated broad dynamic range of detection for both cell lines.  
Increased sensitivity of the bioluminescence assay was also observed compared 
to a traditional MTT-based cell viability assay.  Moreover, a direct relationship 
between luminescence signals and cell number was observed for both cell lines 
using two approaches, luminometry and bioluminescence imaging. The use of 
live animal bioluminescence imaging provides a more physiologically relevant 
context and allows for non-invasive, longitudinal monitoring of animals, again 
avoiding the use of large numbers of animals for research.  These advantages 
notwithstanding, cell-based assays remain indispensable for large-scale screens. 
 
Prior to performing a large-scale screen, we assessed the responsiveness 
of the two engineered cell lines to standard pharmacological and genetic agents.  
Staurosporine, a member of the K252 family of compounds known to inhibit 
protein kinases [322], was used to show sensitivity of the engineered cells to an 
apoptosis-inducing drug.  Cisplatin, a platinum-containing, broad activity anti-
neoplastic and alkylating agent [323], was used to demonstrate the sensitivity of 
cells to a classic chemotherapeutic agent.  Finally, RNA interference using 
siRNAs against GAPDH, a gene involved in vital metabolic functions [324], 
illustrated the utility of these cells for studies involving genetic treatments.  
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The assay was then implemented in a large-scale screen of the 
LOPAC1280 compound library. This library contains 1,280 pharmacologically 
active compounds.  This annotated collection of small molecule modulators and 
FDA-approved drugs impacts most cellular processes and covers all major drug 
target classes.  The LOPAC screen serves as an excellent starting point for 
validating high-throughput assays.  Moreover, it potentially allows the 
identification of drugs that have available human dosage and toxicity information 
as well as the discovery of lead structures for drug development.  Our primary 
screen identified several classes of drugs that reduced SCLC cell viability (Table 
IV-1).  Of these, many have been implicated in fundamental processes 
associated with the etiology of cancer, such as angiogenesis, calcium signaling, 
cell cycle progression, and protein phosphorylation [120].   
 
Interestingly, our screen identified several drug classes that impact 
neuroendocrine pathways known to be involved in SCLC pathogenesis.  SCLC 
cells are characterized by neuroendocrine features such as the expression of ion 
channels, neuropeptides, and neurotransmitters and, as a consequence, are 
electrically excitable [325]. Here, we identified drugs that target adrenoreceptors, 
calcium channels, cholinergic receptors, dopamine signaling, GABA signaling, 
glutamate signaling, K+ channels, Na+ channels, opioid signaling and serotonin 
signaling [326]. 
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We focused the follow-up screen on compounds that target dopamine and 
serotonin signaling as they yielded the highest number of hits.  We did not 
pursue compounds in the protein phosphorylation class given the ubiquitous role 
protein phosphorylation plays in both normal and disease states.  The secondary 
screening results essentially overlapped with those of the primary screen, 
indicating the reliability of the assay.  Furthermore, the dose-dependent reduction 
in cell viability induced by the D2 dopamine receptor antagonist, cortexolone 
maleate, and the serotonin reuptake inhibitor, fluoxetine hydrocholoride, is 
consistent with the critical role of neurotransmitter signaling in the pathogenesis 
of SCLC [327]. 
 
Dopamine signaling has previously been implicated in SCLC [328].  In 
particular, the D2 receptor agonist, bromocriptine, has been shown to have an 
anti-proliferative effect on SCLC cells in vitro and inhibits growth of SCLC tumor 
xenografts [329].  Unexpectedly, we observed that cortexolone maleate, which 
blocks the D2 dopamine receptor, also has an anti-proliferative effect.  In 
addition, serotonin has been shown to act as a mitogenic signal in SCLC, 
activating an autocrine growth loop in these cells [330, 331].  However, we found 
that the serotonin reuptake inhibitor, fluoxetine hydrochloride, known to increase 
serotonin levels, inhibits SCLC growth.  Another serotonin reuptake inhibitor, 
imipramine, has previously been shown to inhibit the development of SCLC 
[128]. Taken together, these findings suggest that SCLC growth may rely on the 
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maintenance of specific levels of neurotransmitters rather than their simple 
absence or presence or alternatively posit functional selectivity of 
neurotransmitter receptors in SCLC. 
 
In conclusion, we have described a bioluminescence-based assay for drug 
discovery in the field of SCLC therapeutics.  Such an assay has not been 
previously applied to SCLC, a disease with very poor prognosis and limited 
treatment outcomes.  The simplicity and speed of the workflow we developed not 
only allows for routine laboratory use but also lends itself to high-throughput 
applications and adaptability to automation.  We have validated this assay 
against a library of pharmacologically active compounds.  That positive hits 
included compounds targeting classic cancer signaling pathways suggests 
internal consistency.  Compounds that target neurotransmission also emerged 
from the screen, reflecting the neuroendocrine nature of SCLC and underscoring 
the role of neurotransmitter signaling in this disease. In particular, perturbation of 
dopamine and serotonin signaling inhibits SCLC cell viability, suggesting the 
utility of these classes of drugs as therapeutic agents against SCLC. 
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CHAPTER V: 
DISCUSSION 
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That theory is worthless.  It isn't even wrong!  
-Wolfgang Pauli 
 
The cloning of nAChRs from brain cDNA libraries in the mid-1980s was a 
watershed event as it opened the window not only to a molecular understanding 
of cholinergic signaling but also to a structural appreciation of how members of 
the superfamily of ligand-gated ion channels function.  As the cloning frenzy 
subsided, tremendous effort was put forth to characterize the pharmacological 
and biophysical properties of nAChRs.  As a result, nAChRs are among the most 
well understood allosteric membrane proteins from a structural and functional 
point of view.  Following the cloning of nAChR subunits, development of novel 
nAChR ligands – agonists, antagonists, and allosteric modulators - for CNS 
disorders became a focus for many drug companies.  Varenicline (Chantix), a 
partial agonist of α4-containing nAChRs, is a product of this endeavor and is now 
a clinically approved drug for smoking cessation [332].  Several other nAChR-
targeted drugs for Alzheimer’s disease, anxiety, depression, pain, schizophrenia, 
and ulcerative colitis are now in clinical trials [333]. 
 
Despite all this progress, one major challenge that remains in the field is 
deciphering the native nAChR subtypes responsible for the myriad functions that 
nAChRs play both in and out of the nervous system.  Identification of these 
subtypes is complicated by the existence of several subunits (i.e., eleven human 
subunits), the numerous ways these subunits can combine (i.e., various 
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homomeric and heteromeric receptors), and the different stoichiometries for each 
subtype (e.g., (α4)2(β2)3 vs. (α4)3(β2)2) [334]. Nevertheless, delineating the role 
of specific subtypes is critical to the understanding the function of nAChRs in 
general and is essential in drug discovery efforts for subtype-selective drugs.    
 
For years, the α4β2 and α7 nAChR subtypes have been the focus of most 
studies in the nAChR field for the reasons that follow.  First, the α4β2 subtype is 
highly expressed in the brain and binds with the highest affinity to nicotine and 
other common nAChR agonists [335].  It is also the subunit most strongly 
upregulated by nicotine exposure [336].  Specifically, chronic nicotine treatment 
increases the number of α4β2 nAChRs in rodent brain, consistent with increased 
α4β2 expression in post-mortem brains of human smokers.  The α7 subtype is 
also highly expressed in the brain, where it undergoes rapid activation and 
desensitization in response to agonists [175]. In addition, the availability of an 
irreversible and highly selective ligand for α7, αBgtx, has facilitated studies with 
this receptor.   
 
A major advance towards understanding the role of other nAChR subtypes 
is the discovery of allelic variations in the genes encoding the α5, α3, and β4 
nAChR subunits that increase risk for nicotine dependence and lung cancer (see 
Chapter I). That polymorphisms in these genes influence risk for these and other 
disorders suggests a pleiotropic role for nAChRs in different cell types [167].  It is 
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quite compelling that results of both hypothesis-free GWAS and hypothesis-
driven candidate-gene studies converged on this gene cluster and that these 
results have been replicated many times over by independent groups using 
different tools and different populations.  
 
In Chapter II, we describe the over-expression of CHNRA5/A3/B4 in 
SCLC.  The high expression of nAChR subunit genes in SCLC is consistent with 
the neuroendocrine phenotype of these cells. Pulmonary neuroendocrine cells 
fare believed to be the precursor cells of SCLC [11].   They exist either as solitary 
cells in the tracheobronchial tract or as clusters called neuroepithelial bodies in 
the intrapulmonary airways.  These cells are normally found in the fetal or 
neonatal lung, where they play a role in lung morphogenesis [337].  They act as 
chemoreceptors that sense oxygen and carbon dioxide levels and respond by 
releasing secretory substances.  The existence of pulmonary neuroendocrine 
cells in the adult suggests a recapitulation of embryonic processes, a common 
theme in carcinogenesis [338]. 
 
Intriguingly, the over-expression of the CHRNA5/A3/B4 genes is also 
consistent with the paraneoplastic syndromes commonly associated with SCLC.  
These syndromes are usually neuroendocrine or neurological in nature; the 
former is caused by ectopic production of bioactive substances such as 
hormones and the latter is due to the production of autoimmune antibodies [339]. 
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Antibodies against nAChRs in the autonomic ganglia are thought to cause 
autonomic neuropathies that accompany SCLC [340].  Speculatively, the over-
expression of α5, α3, and β4 nAChRs in SCLC cells triggers the production of 
these autoimmune antibodies.  The consequent immune-mediated tissue 
destruction is, in fact, associated with favorable prognostic outcomes [339], 
possibly due to the concurrent clearance of cancer cells expressing the 
autoantigens. 
 
As also described in Chapter II, the over-expression of the 
CHRNA5/A3/B4 genes is regulated in part by ASCL1.  Our work on 
CHRNA5/A3/B4 regulation is the first report of a transcription factor regulating 
expression of nAChRs in cancer cells.  It also provides a link between nAChR 
signaling and the Notch pathway, a signaling pathway involved in normal 
morphogenesis as well as malignant transformation [341]. Notch receptors are 
activated by multiple alternative ligands (e.g., Delta, Jagged).  Ligand binding 
leads to the proteolytic cleavage of the intracellular domain of the receptor, which 
in turn, translocates to the nucleus and forms part of a transcriptional machinery 
that regulates target genes.  One of the best-described Notch target is the 
transcriptional repressor, Hes (and Hes-related proteins) [341].  Hes represses 
the expression of ASCL1, such that cells that express Hes do not express 
ASCL1, and vice-versa.  For instance, neuroendocrine cells in the lungs express 
ASCL1, while non-neuroendocrine cells express Hes-1. Similarly, SCLC cells 
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express ASCL1 but lack Hes-1 expression, while the opposite is true for NSCLC 
cells [342].   
 
The use of genetically engineered mouse models has further shed light on 
the role of ASCL1 in lung development. mASH1 mutant mice lack 
neuroendocrine cells and die within 12 hours of birth from hypoventilation [343].  
In contrast, Hes-1 null mice exhibit precocious neuroendocrine differentiation 
[344]. Transgenic expression of ASCL1 in non-neuroendocrine cells of the 
airways, along with SV40 large T antigen, induces lung tumors with a NSCLC-
neuroendocrine phenotype [345].  Constitutive expression of ASCL1 alone leads 
to extensive cell proliferation in the airways without neuroendocrine 
differentiation, suggesting that ASCL1 expression with concomitant loss of p53 
and Rb (due to the T antigen) promotes the development of neuroendocrine lung 
tumors.   
 
Analysis of ASCL1 transcriptional targets hints at mechanisms by which 
ASCL1 functions in lung cancer.  One study using pancreatic neuroendocrine 
tumors described components of the Wnt signaling pathway as targets for 
ASCL1 [346].  Another group using embryonic brain reported ASCL1 regulation 
of a large number of genes involved in cell cycle regulation [347].  In SCLC cells, 
the stem cell markers CD133 and aldehyde dehydrogenase 1A1 (ALDH1A1) 
were identified as ASCL1 targets, advocating the involvement of ASCL1 in tumor 
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initation [348].  Another group describes ASCL1 repression of E-cadherin, 
suggesting a role for ASCL1 in epithelial-mesenchymal transition [349].  Our 
findings add CHRNA5/A3/B4 to the list of ASCL1 responder genes.  We propose 
a mechanism by which upregulation of ASCL1 in SCLC cells causes a 
corresponding upregulation of α5α3β4 nAChRs, leading to the potentiation of the 
tumorigenic effects of nicotine and acetylcholine. 
 
Importantly, the over-expression of CHRNA5/A3/B4 in SCLC supports the 
hypothesis that these genes play a direct role in lung cancer.  As described in 
Chapter III, their function involves maintenance of SCLC cell viability and 
modulation of tumor growth and incidence.  We envisage a mechanism wherein 
α5α3β4 nAChRs act as upstream mediators of nicotine and/or acetylcholine-
activated cancer signaling pathways (Figure V-1).  A number of such signaling 
pathways have been described, including the proliferative Ras-Raf-MAPK 
pathway and the anti-apoptotic PI3K-Akt-Bad pathway.  Investigation of the 
specific pathways mediated by α5α3β4 nAChRs should expound on the role of 
this subtype in SCLC. 
 
SCLC remains one of the deadliest types of cancers, for which no major 
advancements in terms of therapy have been made in the last three decades 
[314].  In terms of SCLC research, part of the reason may involve the difficulty in 
obtaining human SCLC tumor samples.  Not only is SCLC less common than 
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other types of lung cancer, SCLC patients also present with metastasis at the 
diagnosis, precluding surgical resection of tumors.  From a biological standpoint, 
the neuroendocrine phenotype of SCLC may be a huge factor in the 
aggressiveness and chemoresistant nature of the deisease.  The numerous 
neurotransmitters and neuropeptides produced by SCLC triggers its own 
proliferative state. Furthermore, the anti-apoptotic pathways evoked by nicotine 
and/or acetylcholine may interfere with the actions of chemotherapeutic drugs. 
Results from our high-throughput screen suggest that targeting these 
neuroendocrine pathways directly may be a viable therapeutic approach for 
SCLC. 
 
Future Directions 
One of the major limitations in the nAChR field is the absence of high 
quality antibodies for use in immunoassays. A recent evaluation of nAChR 
antibodies showed that several supposedly subunit-specific antibodies against 
nAChRs immunoreact with both wild-type and subunit knockout mice [350].  This 
precludes the use of these reagents for immunodetection methods and calls into 
question previously published work that made use of these antibodies.  In terms 
of our own research, the lack of this valuable tool hindered us from performing 
Western blot or immunostaining experiments to determine protein expression of 
nAChR subunits in normal and lung cancer cells. Future development of high 
quality antibodies against nAChRs would allow immunodetection experiments to 
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be carried out.  Furthermore, these antibodies would be useful in co-
immunoprecipitation experiments for identification of nAChR subtypes.  
 
We were able to circumvent this problem by using the epibatidine 
radioligand assay to determine the effect of ASCL1 knockdown on the total 
nAChR levels on the cell membrane.  Though this results shows that ASCL1 
knockdown decreases total nAChR protein levels, it would be interesting to 
measure the effect of ASCL1 knockdown specifically on α3β4 nAChR levels.  
Development of radiolabeled α-conotoxin AuIB would facilitate such an 
experiment.  Currently, there are no available α5α3β4 nAChR-selective ligands, 
though it is hoped that cone snail venoms or chemical entities being developed 
by pharmaceutical companies may someday provide this tool. 
 
We have demonstrated that ASCL1 regulates expression of 
CHRNA5/A3/B4 but we have not shown whether this regulation is via direct 
binding to the E-boxes found in the CHRNA5/A3/B4 promoter regions.  Our 
preliminary work using chromatin immunoprecipitation (ChIP) assays suggests 
that ASCL1 directly binds to one of the E-boxes in the CHRNA3 promoter (see 
Appendix II).  This work can be extended to include the other E-boxes in the 
locus.  Additionally, site-directed mutagenesis of the E-boxes should identify 
functional binding sites for ASCL1.  We have also initiated ASCL1 transactivation 
experiments showing that forced expression of ASCL1 activates the CHRNA3 
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promoter, while ASCL1 knockdown decreases the activity of the promoter 
(Appendix III).  This work can be extended to include the CHRNA5 and CHRNB4 
promoters as well.  Co-immunoprecipitation experiments with known 
transactivators of CHRNA5/A3/B4 would also identify ASCL1 binding partners 
and elucidate the transcriptional machinery regulating CHRNA5/A3/B4 
expression in SCLC.   
 
Though we observed robust regulation of CHRNA3 and CHRNB4 by ASCL1, we 
only observed a modest regulation of CHRNA5.  That CHRNA5 is transcribed in 
the opposite direction as CHRNA3 and CHRNB4 may offer one possible 
explanation.  A unique set of transcription factors may govern CHRNA5 
expression from that direction.  The presence of E-boxes in the CHRNA5 
promoter suggests other basic helix-loop-helix transcription factors may play a 
role.  One candidate for future studies is N-myc, often amplified in SCLC but not 
in NSCLC [351].  
 
With regards to our functional work, we have shown that the 
CHRNA5/A3/B4 genes are necessary for maintenance of SCLC cell viability, an 
important observation on its own.  However, we have not shown whether the 
decrease in cell viability observed upon CHRNA5/A3/B4 knockdown is due to a 
decrease in cell proliferation or an increase in cell death.  We have begun to set 
up experiments to address this question.  BrdU labeling will be performed to 
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determine the effect of CHRNA5/A3/B4 knockdown on cell proliferation.  Western 
blot analysis will also be utilized to interrogate the MAPK proliferative pathway.  
Levels of phosphorylated versions of MAPK pathway components will be 
determined upon CHRNA5/A3/B4 knockdown.  Experiments to determine the 
effect of CHRNA5/A3/B4 knockdown on cell death would be performed in 
parallel. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
assays will be performed to determine effect of CHRNA5/A3/B4 knockdown on 
apoptosis.  The PI3K-Akt apoptotic pathway will also be interrogated using 
Western blot analysis.  
 
Nicotine and acetylcholine signaling mediate other cancer-related 
processes and the effect of CHRNA5/A3/B4 knockdown on these processes 
should also be investigated.  For example, soft agar assays can be performed to 
determine the effect of CHRNA5/A3/B4 knockdown on anchorage-independent 
growth.  Our preliminary work suggests that CHRNA3 knockdown decreases 
both the number and size of colonies that form in soft agars (Appendix IV).  This 
work can be extended to CHRNA5 and CHRNB4.  Other in vitro assays include 
endothelial tube formation assays for angiogenesis or Boyden chamber assays 
for migration/invasion. 
 
Our in vivo work utilizing the xenograft tumor model showed inhibition of 
tumor growth and incidence with CHRNA5 silencing.  To date, we have not 
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observed significant decreases in tumor growth upon CHRNA3 and CHRNB4 
knockdown.  The lack of a proper tumor microenvironment may obscure the 
effects of CHRNA3 and CHRNB4 knockdown.  The use of an orthotopic model 
(i.e., via intrathoracic injections) may be a useful future approach.  The lung 
colonization model may also be used to allow tumor cells to reach the lung via 
tail vein injections.  Though primarily used as a metastasis assay, this model may 
provide the proper microenvironment for SCLC cells.  
 
The functional assays described here mostly involve loss-of-function 
experiments.  Corresponding gain-of-function experiments should be performed.  
Similar cell viability and xenograft assays can be performed using transient and 
stable expression of CHRNA5/A3/B4 expression constructs, respectively, into 
SCLC cells.  One possible problem with over-expression experiments is that 
CHRNA5/A3/B4 expression may already be at saturation levels, such that further 
increases in expression may not yield additional measurable phenotypes.  
Another approach would be to develop knock-in mouse models expressing the 
rs16969968 SNP, with and without the risk allele.  These can then be used to 
determine susceptibility to lung cancer in the presence and absence of nicotine.  
Such an experiment would demonstrate whether the risk allele confers lung 
cancer susceptibility independent of nicotine exposure. 
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Finally, we have developed and validated a bioluminescence-based viability 
assay for large-scale screening of compounds against SCLC.  However, this 
project is only at its inception.  Further validation of other positive hits in the 
screen will be performed.  Interesting hits will be further investigated using both 
in vitro and in vivo assays.  Chemical modification of compounds of interest to 
improve activity and/or other clinically relevant properties may also be worth 
pursuing.  This assay can also be applied to even larger libraries of compounds 
or for large-scale RNA interference screens. Ultimately, the goal of these 
experiments is to enhance currently available therapeutics against SCLC. 
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APPENDIX I 
 
DMSO Treatment 
 
 
 
Figure A-I. DMSO tolerance of DMS-53 luc+ cells.  Cells were treated either 
with 0.5% or 1% DMSO in complete medium for 24 hours.  Cells in medium 
alone served as untreated controls.  No significant difference in cell viability 
was observed after DMSO treatment. 
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APPENDIX II 
 
Chromatin Immunoprecipitation 
 
 
 
 
 
Figure A-II. ASCL1 binds to the CHRNA3 promoter.  Chromatin 
immunoprecipitation (ChIP) assay shows enrichment of the CHRNA3 promoter 
in samples immunoprecipitated with an ASCL1 antibody.  ChIP assays were 
performed using the ChIP-IT Express kit (Activ Motif).  Specifically, DMS-53 
cells were subjected to formaldehyde-crosslinking followed by sonication to 
obtain DNA fragments with an average size of 500bp.  Chromatin samples 
were then incubated with an ASCL1 ChIP-grade antibody (Santa Cruz 
Biotechnology) overnight at 4oC.  RNA Polymerase II antibodies and normal 
IgG were used as positive and negative controls for immunoprecipitation.  A no-
antibody control was also performed.  Protein G-coated magnetic beads were 
co-incubated with the samples for pull-down of chromatin-antibody complexes.  
Beads were collected using a magnetic bar and washed several times followed 
by chromatin elution.  Reverse-crosslinking and Proteinase K digestion was 
performed in preparation for PCR.  To amplify the promoter region of CHRNA3, 
the forward primer 5’-GGAAACCTGGGACAGAAACTGA-3’ and the reverse 
primer 5’-GGCGGCGTCTTGACAGAT-3’ were used. Input DNA was used as a 
positive control template while water was used as a no-template control. I - 
Input; R - RNA polmerase II; A - ASCL1; NI - Normal IgG; NA - No antibody; W 
- Water.  
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APPENDIX III 
 
Luciferase Reporter Assay 
 
 
 
 
Figure A-III. Luciferase reporter assay shows decrease in CHRNA3 promoter 
activity upon ASCL1 knockdown and increase in CHRNA3 promoter activity 
upon ASCL1 over-expression. The CHRNA3  promoter region was subcloned 
upstream of a luciferase reporter gene of the parent vector, pGL3-Basic 
(Promega).  For knockdown experiments, reporter plasmids were transfected 
into DMS-53 cells along with an ASCL1 siRNA (s1656, Applied Biosystems) 
using Lipofectamine 2000 (Invitrogen).  For transactivation experiments, 
reporter plasmids were co-transfected with the ASCL1 gene subcloned into the 
expression vector, pcDNA3.1 (Invitrogen).  A β-galactosidase expression vector 
was co-transfected in each sample for normalization.  Cells were harvested 48 
hours after transfection and assayed for luciferase (Luciferase Assay System, 
Promega) and β-galactosidase (Galacto-Star System, Applied Biosystems) 
activity in a Lumimark microplate luminometer (Bio-Rad).  ** = p < 0.01, *** = p 
< 0.001 compared to No Promoter sample; n = 4; ANOVA-Tukey. 
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APPENDIX IV 
 
Soft Agar Assay 
 
 
 
 
 
Figure A-IV.  CHRNA3 knockdown decreases number and size of colonies in 
soft agar assay. DMS-53 cells treated with a non-silencing or CHRNA3 
shRNAmir were grown in soft agar plates at 37oC for 21 days.  Colonies were 
visualized by staining with 0.005% crystal violet and counted using the 
Labworks 4.5 software (UVP Bioimaging Systems).  
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